PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24607939-6 2014 Interestingly, liposomal dexamethasone induced proinflammatory cytokine secretion (specifically TNF, IL1beta, IL6) in unstimulated cells, but reduced this response under inflammatory conditions. Dexamethasone 25-38 interleukin 6 Homo sapiens 110-113 24526008-4 2014 RESULT: Exogenous IL-10 (10(-8 )M) significantly (P<0.05) inhibited the endotoxin-stimulated release of IL-6, IL-8 and tumor necrosis factor by 63 to 82% with no significant effect by DEX and BETA. Dexamethasone 187-190 interleukin 6 Homo sapiens 107-111 24032470-7 2014 The corticosteroid dexamethasone inhibits S1P-induced IL-6 protein secretion and mRNA expression, but CREB/CRE transrepression, inhibition of IL-6 mRNA stability, or subcellular relocation of MSK1 were not responsible for the repressive effects of dexamethasone. Dexamethasone 19-32 interleukin 6 Homo sapiens 54-58 23625984-10 2014 Dexamethasone downregulated pro-inflammatory mediator (IL-1beta, IL-6, TNFalpha, IFNgamma, MMP-9, TIMP-1, CCL3 and CXCL8) mRNAs but did not modify expression of vascular remodelling factors (platelet derived growth factor, MMP-2 and collagens I and III). Dexamethasone 0-13 interleukin 6 Homo sapiens 65-69 23771534-0 2013 MIF attenuates the suppressive effect of dexamethasone on IL-6 production by nasal polyp. Dexamethasone 41-54 interleukin 6 Homo sapiens 58-62 23944957-10 2014 IL-6 was less suppressible by dexamethasone in patients with nonsevere and severe asthma, compared with healthy subjects. Dexamethasone 30-43 interleukin 6 Homo sapiens 0-4 24126150-3 2014 Therefore, the objective of this study was to examine the inhibitory effect of an exogenous GC (dexamethasone, DEX) on leptin- and lipopolysaccharide (LPS)-induced IL-6 production by peripheral blood mononuclear cells (PBMCs) ex vivo in obese subjects compared to normal-weight subjects. Dexamethasone 96-109 interleukin 6 Homo sapiens 164-168 26155135-3 2014 The results showed that both DEX and CsA dose-dependently inhibited the production of eleven cytokines: interleukin (IL)-2, IL-4, IL-5, IL-6, IL-13, IL-17, interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF). Dexamethasone 29-32 interleukin 6 Homo sapiens 136-140 23791923-7 2013 Furthermore, based on interference with IL-6 secretion, we show potential (chemical) interactions between dexamethasone and sugammadex. Dexamethasone 106-119 interleukin 6 Homo sapiens 40-44 23602849-6 2013 We show here that the activity of sbIL-6P was significantly induced by pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFalpha), IL-6 and IL-2, as well as by lipopolysaccharide (LPS), but significantly repressed by dexamethasone. Dexamethasone 232-245 interleukin 6 Homo sapiens 36-40 23771534-4 2013 AIM: To investigate the presence of MIF in nasal polyp tissues and the influence of a MIF activity inhibitor on dexamethasone effects on IL-6 production. Dexamethasone 112-125 interleukin 6 Homo sapiens 137-141 23771534-10 2013 Dexamethasone at concentration 1-100 microM caused a statistically significant dose-dependent suppression of IL-6 production by polyp tissue cultures. Dexamethasone 0-13 interleukin 6 Homo sapiens 109-113 23771534-12 2013 CONCLUSIONS: MIF, presence in polyp tissue, attenuates the suppressive effect of dexamethasone on the production of IL-6 by this tissue, since the simultaneous use of its inhibitor ISO-1 leads to an enhancement of dexamethasone activity. Dexamethasone 81-94 interleukin 6 Homo sapiens 116-120 23600327-5 2013 The constitutive expression of RANKL and Ki-67 and the production of IL-6 and IL-8 were significantly inhibited by Dex treatment. Dexamethasone 115-118 interleukin 6 Homo sapiens 69-73 23681030-16 2013 Dexamethasone use significantly reduced postoperative levels of C-reactive protein (P = .01) and interleukin 6 and interleukin 1beta (P = .02), fatigue (P = .01), and overall pain during the first 24 postoperative hours (P = .04), as well as the total analgesic (ketorolac tromethamine) requirement (P = .04). Dexamethasone 0-13 interleukin 6 Homo sapiens 97-110 23600327-6 2013 Further, Dex significantly suppressed the stimulatory effects of LPS on RANKL and Ki-67 expression and on IL-6 and IL-8 production. Dexamethasone 9-12 interleukin 6 Homo sapiens 106-110 23246534-3 2013 METHODS: Changes in lipopolysaccharide (LPS)-induced interleukin (IL)-6 production and inhibition of IL-6 production by dexamethasone in reaction to the Trier Social Stress Test (TSST) were assessed in forty-six healthy school teachers to test whether chronic work stress is accompanied by alterations in inflammatory activity and glucocorticoid sensitivity of the innate immune system. Dexamethasone 120-133 interleukin 6 Homo sapiens 101-105 23439564-4 2013 With the combined use of dexamethasone (0.01 mug/mL) and GA (10 mug/mL), the suppression of ICAM-1 expression and CCL5 and IL-6 release of IL-33-activated KU812 cells were significantly greater than the use of GA alone (all p < 0.05). Dexamethasone 25-38 interleukin 6 Homo sapiens 123-127 23246534-4 2013 RESULTS: High ERI was associated with an increase in pro-inflammatory potential, reflected in elevated IL-6 production before and after stress and with a lower capacity of dexamethasone to suppress IL-6 production in vitro over all measurement time points. Dexamethasone 172-185 interleukin 6 Homo sapiens 198-202 23052185-9 2013 Impregnation of lipopolysaccharide-stimulated macrophages with the glucocorticoid dexamethasone further enhanced Zip14 expression while reducing interleukin-6 and tumor necrosis factor-alpha production. Dexamethasone 82-95 interleukin 6 Homo sapiens 145-190 23063726-6 2013 In the presence of BMSCs, Dex plus BTZ combination inhibited ionizing radiation-induced interleukin 6 secretion from BMSCs and induced myeloma cytotoxicity. Dexamethasone 26-29 interleukin 6 Homo sapiens 88-101 23160983-9 2013 Dexamethasone"s trans-activation of GILZ and trans-repression of NF-kB-driven IL-6 expression were both inhibited by IL2 + 4; IL17 + IL23 antagonized Dex trans-repression in PBMC from asthmatics. Dexamethasone 0-13 interleukin 6 Homo sapiens 78-82 23484124-6 2013 By comparison, exposure to dexamethasone reduced TNF- alpha , IL-6, and IL-1 beta production, while at this time point it increased resistin protein secretion. Dexamethasone 27-40 interleukin 6 Homo sapiens 62-66 23033490-8 2012 In contrast, dexamethasone suppressed cell invasion, the expression of its related genes [MMP-2/MMP-9, interleukin (IL)-6, VEGF], and the activity of MMP-2/MMP-9, and also induced mesenchymal-to-epithelial transition. Dexamethasone 13-26 interleukin 6 Homo sapiens 103-121 22791764-13 2012 Up-regulation of RANKL and OPG mRNA by IL-6 was suppressed by dexamethasone. Dexamethasone 62-75 interleukin 6 Homo sapiens 39-43 22300324-7 2012 KEY RESULTS: TGF-beta (40-400 pM) reduced the maximum inhibitory effect of dexamethasone on IL-1alpha-induced IL-6 and CXCL8 production. Dexamethasone 75-88 interleukin 6 Homo sapiens 110-114 22289904-6 2012 RESULTS: Pretreatment with dexamethasone led to a significant decrease in myocardial expression of IL-6, IL-8, IL-1beta, and TNF-alpha messenger RNA and to a decrease in protein synthesis of TNF-alpha. Dexamethasone 27-40 interleukin 6 Homo sapiens 99-103 22931661-7 2012 After high dose DXM treatment, the levels of IFN-alpha, IL-6 and TNF-alpha decreased without significant difference compared with normal controls (P > 0.05). Dexamethasone 16-19 interleukin 6 Homo sapiens 56-60 22285171-7 2012 Dexamethasone pretreatment prior to LPS exposure significantly decreased IL-6 and IL-8 levels in both cell lines. Dexamethasone 0-13 interleukin 6 Homo sapiens 73-77 22471522-3 2012 IL-6 treatment increased myeloma cell resistance to agents that induce oxidative stress, including IR (ionizing radiation) and Dex (dexamethasone). Dexamethasone 127-130 interleukin 6 Homo sapiens 0-4 22471522-3 2012 IL-6 treatment increased myeloma cell resistance to agents that induce oxidative stress, including IR (ionizing radiation) and Dex (dexamethasone). Dexamethasone 132-145 interleukin 6 Homo sapiens 0-4 22471522-9 2012 The present study provides evidence that increases in MnSOD expression mediate IL-6-induced resistance to Dex and radiation in myeloma cells. Dexamethasone 106-109 interleukin 6 Homo sapiens 79-83 21956421-12 2011 The induction of IL-6 can be blocked by dexamethasone, a chemical inhibitor of Akt/Pkb, and by knocking down Akt with a specific small interfering RNA. Dexamethasone 40-53 interleukin 6 Homo sapiens 17-21 22309277-9 2012 CRSwNP cultures were more sensitive than controls to dexamethasone (1 microg/ml) dependent IL-6 and IL-8 suppression. Dexamethasone 53-66 interleukin 6 Homo sapiens 91-95 21069571-9 2011 Dexamethasone attenuated LPS-induced IL-1 beta (IC(50) = 70 nM), IL-6 (IC(50) = 58 nM) and TNF-alpha (IC(50) = 44 nM) release, whereas celecoxib, a specific COX-2 inhibitor showed marked reduction in LPS-induced PGE(2) (IC(50) = 23 nM) production. Dexamethasone 0-13 interleukin 6 Homo sapiens 65-69 21664353-11 2011 A further proof was achieved by DEX inhibition for IL1-beta-stimulated IL-6 and COX-2 gene expression. Dexamethasone 32-35 interleukin 6 Homo sapiens 71-75 21272678-12 2011 In human mononuclear leukocyte, isoforskolin (50, 100, and 200 muM) and dexamethasone (10 muM) pre-incubation lowered lipopolysaccharide (2 mug/mL) induced secretion of the cytokine TNF-alpha, and interleukins (IL)-1beta, IL-6, and IL-8. Dexamethasone 72-85 interleukin 6 Homo sapiens 222-226 23268452-8 2011 Dexamethasone was found to decrease IL-6 production, while salbutamol increased it. Dexamethasone 0-13 interleukin 6 Homo sapiens 36-40 20946124-11 2011 Dexamethasone (100 nM) partially inhibited release of both IL-6 and IL-8. Dexamethasone 0-13 interleukin 6 Homo sapiens 59-63 21189358-6 2011 Dex suppressed genes in immune/inflammatory (IL-6, IL-8, and MCP-1, expressed in nonadipocytes) and proapoptotic pathways, yet induced genes related to the acute-phase response (SAA, factor D, haptoglobin, and RBP4, expressed in adipocytes) and stress/defense response. Dexamethasone 0-3 interleukin 6 Homo sapiens 45-49 20826566-4 2010 When cells were pretreated with dexamethasone, a prototypic glucocorticoid, ATP-induced IL-6 production was enhanced in a time- and dose-dependent manner. Dexamethasone 32-45 interleukin 6 Homo sapiens 88-92 22121382-8 2011 Salmeterol increased, while dexamethasone and fluticasone decreased RV-induced IL-6 and IL-8 (P<0.05). Dexamethasone 28-41 interleukin 6 Homo sapiens 79-83 22065919-7 2011 IL-6 levels decreased in dexamethasone group and anti-oxidants group. Dexamethasone 25-38 interleukin 6 Homo sapiens 0-4 20826566-7 2010 Cells treated with dexamethasone induced mRNA expression of the purinergic P2Y(2) receptor (P2Y(2)R) 1.8- +- 0.1-fold and, when stimulated with ATP, enhanced Ca(2+) release and augmented IL-6 mRNA expression. Dexamethasone 19-32 interleukin 6 Homo sapiens 187-191 20693312-7 2010 After 48-h exposure of cells to DXM or BTM, IL-6 caused a significantly greater increase in SP-B mRNA levels (28.1-fold) than IL-6 or glucocorticoids alone. Dexamethasone 32-35 interleukin 6 Homo sapiens 44-48 21170263-3 2010 Dex was found to inhibit the release of interleukin-6 from irradiated BMSCs, which is an established myeloma cell proproliferative cytokine. Dexamethasone 0-3 interleukin 6 Homo sapiens 40-53 21039738-5 2010 Additionally, we determined whether induction of monocyte NF-kappaB signalling, TNF-alpha and IL-6 production with lipopolysaccharide (LPS), a TLR4 ligand, can be altered with dexamethasone, chloroquine or both. Dexamethasone 176-189 interleukin 6 Homo sapiens 94-98 21039738-7 2010 However, neither dexamethasone nor chloroquine had major influence on TLR4 expression in vitro or suppressed LPS-induced NF-kappaB activation in monocytes, although dexamethasone decreased TNF-alpha and IL-6 production. Dexamethasone 165-178 interleukin 6 Homo sapiens 203-207 20693312-7 2010 After 48-h exposure of cells to DXM or BTM, IL-6 caused a significantly greater increase in SP-B mRNA levels (28.1-fold) than IL-6 or glucocorticoids alone. Dexamethasone 32-35 interleukin 6 Homo sapiens 126-130 20693312-9 2010 Both DXM and BTM could potentiate IL-6-induced phosphorylation of STAT3. Dexamethasone 5-8 interleukin 6 Homo sapiens 34-38 20545708-7 2010 The expression of IL-6 in response to IL-17A and F and dexamethasone was determined by Q-RT-PCR using primary airway epithelial cells from normal and asthmatic subjects. Dexamethasone 55-68 interleukin 6 Homo sapiens 18-22 20545708-13 2010 Dexamethasone significantly decreased the IL-17-induced IL-6 expression in cells from normal individuals but not in those from asthmatics (P< or =0.05). Dexamethasone 0-13 interleukin 6 Homo sapiens 56-60 20231081-6 2010 Compared to vehicle-treated cells, all antidepressants inhibited dexamethasone (DEX, 10-100nM) inhibition of LPS-stimulated IL-6 levels (p values ranging from 0.007 to 0.1). Dexamethasone 65-78 interleukin 6 Homo sapiens 124-128 20445007-10 2010 In contrast, delayed DEX addition significantly suppressed PAM-induced IL-1beta, IL-6, or IL-8 and also suppressed LPS-induced IL-1beta and IL-8. Dexamethasone 21-24 interleukin 6 Homo sapiens 81-85 20845101-11 2010 Dexamethasone significantly reduced postoperative levels of CRP (p = 0.01), IL-6 and IL-1 (p < 0.05), fatigue (p = 0.01) and overall pain during the first 24 postoperative hours (p < 0.05) and the total requirement of analgesic (ketorolac) (p < 0.05). Dexamethasone 0-13 interleukin 6 Homo sapiens 76-80 20231081-6 2010 Compared to vehicle-treated cells, all antidepressants inhibited dexamethasone (DEX, 10-100nM) inhibition of LPS-stimulated IL-6 levels (p values ranging from 0.007 to 0.1). Dexamethasone 80-83 interleukin 6 Homo sapiens 124-128 19847865-8 2009 Dexamethasone was associated with significantly lower peritoneal fluid interleukin (IL) 6 and IL-13 concentrations on day 1, and these correlated with changes in the ICFS score. Dexamethasone 0-13 interleukin 6 Homo sapiens 71-89 20423350-8 2010 Addition of dexamethasone with salmeterol repressed IL-6 and IL-8 release to levels that were similar to the repression achieved in the absence of salmeterol. Dexamethasone 12-25 interleukin 6 Homo sapiens 52-56 20731121-0 2010 [Influence of polyoxidonium on IL-1 beta, TNF-alpha and IL-6 production by mononuclears and monocytes under the dexamethasone effect]. Dexamethasone 112-125 interleukin 6 Homo sapiens 56-60 19826119-13 2009 Reducing the number of weekly treatments per cycle from four to three and adding prophylactic dexamethasone, which abrogated interleukin-6 release and CRS (P < or = .01), resulted in improved tolerability and treatment delivery. Dexamethasone 94-107 interleukin 6 Homo sapiens 125-138 20346081-9 2010 Dexamethasone, at 50 microg/ml, decreased the viability of HRECs stimulated by IL-1alpha, IL-1beta, IL-6 and VEGF without hyalocytes but could not decrease the viability of HRECs cocultured. Dexamethasone 0-13 interleukin 6 Homo sapiens 100-104 19939912-8 2010 Selective GR stimulation of white adipocytes with dexamethasone inhibited the expression of interleukin 6 (IL6), monocyte chemoattractant protein-1 (MCP1 or CCL2 as listed in the MGI Database), tumour necrosis factor-alpha, chemerin and leptin. Dexamethasone 50-63 interleukin 6 Homo sapiens 92-105 19939912-8 2010 Selective GR stimulation of white adipocytes with dexamethasone inhibited the expression of interleukin 6 (IL6), monocyte chemoattractant protein-1 (MCP1 or CCL2 as listed in the MGI Database), tumour necrosis factor-alpha, chemerin and leptin. Dexamethasone 50-63 interleukin 6 Homo sapiens 107-110 19818417-8 2010 Both treatments combined caused the greatest suppression of gene expression; -4.47. qPCR also showed that IL-1beta, GM-CSF and IL-6 mRNA levels were significantly reduced by CSE and further suppressed by dexamethasone. Dexamethasone 204-217 interleukin 6 Homo sapiens 127-131 22966259-12 2010 The change in serum interleukin-6 levels was significantly associated with a response to DXM (P=0.0065). Dexamethasone 89-92 interleukin 6 Homo sapiens 20-33 19181644-7 2009 RESULTS: In vitro, IL-1Ra was superior to dexamethasone at inhibiting IL-6 production; maximal IL-6 inhibition and apoptosis induction were achieved by addition of both IL-1Ra and dexamethasone. Dexamethasone 42-55 interleukin 6 Homo sapiens 70-74 19525101-7 2009 RESULTS: Dexamethasone enhanced the phagocytic capacity of A549 cells and inhibited the production of IL-6 and IL-8 from A549 cells stimulated by LPS. Dexamethasone 9-22 interleukin 6 Homo sapiens 102-106 19465513-7 2009 TNFalpha-induced eotaxin, RANTES, and IL-6 as well as PDGF-BB-induced IL-6 expression was inhibited by DMF and by dexamethasone from asthmatic and nonasthmatic ASMC, but the combination of both drugs showed no glucocorticoid sparing effect in either of the two groups. Dexamethasone 114-127 interleukin 6 Homo sapiens 38-42 19465513-7 2009 TNFalpha-induced eotaxin, RANTES, and IL-6 as well as PDGF-BB-induced IL-6 expression was inhibited by DMF and by dexamethasone from asthmatic and nonasthmatic ASMC, but the combination of both drugs showed no glucocorticoid sparing effect in either of the two groups. Dexamethasone 114-127 interleukin 6 Homo sapiens 70-74 19406240-7 2009 GR function was assessed by measuring the inhibitory effect of dexamethasone on constitutive and IL-1beta-inducible IL-6 and osteoprotegerin (OPG) production. Dexamethasone 63-76 interleukin 6 Homo sapiens 116-120 19406240-8 2009 In PC-3 cells, IL-1beta stimulated IL-6 and OPG release, and dexamethasone dose-dependently inhibited IL-1beta-inducible IL-6 release, and constitutive and IL-1beta-inducible OPG release. Dexamethasone 61-74 interleukin 6 Homo sapiens 121-125 19452017-10 2009 The poly(I:C)-induced expressions of IL-6 and IL-8 were down-regulated by both DEX and CsA, while the expressions of IFN-beta and TLR3 were suppressed by DEX alone. Dexamethasone 79-82 interleukin 6 Homo sapiens 37-41 19101504-5 2009 Expression levels of IL-6, bFGF, and GRO in cultured NP were downregulated by dexamethasone (DEX) treatment, while MCP-1 expression was not suppressed. Dexamethasone 78-91 interleukin 6 Homo sapiens 21-25 19138532-3 2009 The results revealed that DEX nonspecifically and dose-dependently inhibited the production of 12 cytokines (IL-2, IFN-gamma, TNF-alpha, IL-8, IL-1beta, IL-17, IL-4, IL-5, IL-6, IL-10, IL-13, and G-CSF). Dexamethasone 26-29 interleukin 6 Homo sapiens 172-176 19525101-9 2009 CONCLUSIONS: The present study showed that all of the investigated anti-asthmatic drugs including dexamethasone, aminophylline and terbutaline play an anti-inflammatory effect by decreasing the release of IL-6 and IL-8 induced by LPS. Dexamethasone 98-111 interleukin 6 Homo sapiens 205-209 19737233-8 2009 Tumour necrosis factor (TNF)-alpha, interleukin (IL)-6 and growth-related oncogene (GRO)-alpha displayed the greatest sensitivity to dexamethasone in COPD patients, while IL-8, granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) were the least sensitive. Dexamethasone 133-146 interleukin 6 Homo sapiens 36-54 19344406-0 2009 Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Dexamethasone 105-118 interleukin 6 Homo sapiens 23-36 19344406-3 2009 CNTO 328 potently increased the cytotoxicity of dex in IL-6-dependent and -independent human myeloma cell lines (HMCLs), including a bortezomib-resistant HMCL. Dexamethasone 48-51 interleukin 6 Homo sapiens 55-59 19135383-4 2009 We found that LPIL exerted a smaller effect on gene transcription than Dex; however, IL-1beta-inducible target genes such as the CXCL type chemokines IL-8, IL-1beta and IL-6 were all clearly suppressed by LPIL to the same degree as by Dex. Dexamethasone 235-238 interleukin 6 Homo sapiens 169-173 19101504-5 2009 Expression levels of IL-6, bFGF, and GRO in cultured NP were downregulated by dexamethasone (DEX) treatment, while MCP-1 expression was not suppressed. Dexamethasone 93-96 interleukin 6 Homo sapiens 21-25 19181644-7 2009 RESULTS: In vitro, IL-1Ra was superior to dexamethasone at inhibiting IL-6 production; maximal IL-6 inhibition and apoptosis induction were achieved by addition of both IL-1Ra and dexamethasone. Dexamethasone 180-193 interleukin 6 Homo sapiens 95-99 18719648-7 2008 To study GC-sensitivity in vitro, we performed dose-response studies of DEX-induced suppression of interleukin-6 (IL-6) secretion in skin fibroblast cultures. Dexamethasone 72-75 interleukin 6 Homo sapiens 99-112 18775652-2 2008 Therefore, we investigated the influence of cortisol and dexamethasone on the in vitro production of TNF-alpha and IL-6 in blood cells of depressed inpatients at admission, in the course of MDD and in healthy controls. Dexamethasone 57-70 interleukin 6 Homo sapiens 115-119 17629591-4 2009 In addition, we demonstrated that Hsp20, HspB2 and HspB8 induced interleukin-6 production in cultured pericytes and astrocytes, which could be antagonized by dexamethasone, whereas other sHsps and A beta were inactive, suggesting that sHsps may be among the key mediators of the local inflammatory response associated with HCHWA-D and AD lesions. Dexamethasone 158-171 interleukin 6 Homo sapiens 65-78 19139110-8 2009 INCB20 also abrogated the protective effect of IL-6 against dexamethasone by blocking phosphorylation of SHP-2 and AKT. Dexamethasone 60-73 interleukin 6 Homo sapiens 47-51 19365148-6 2009 GC sensitivity was assessed in vitro as the ability of DEX to inhibit lipopolysaccharide-stimulated production of the cytokines interleukin 1-beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in a whole-blood assay. Dexamethasone 55-58 interleukin 6 Homo sapiens 159-172 19365148-7 2009 RESULTS: After exposure to DEX in vivo, inhibition of IL-6 and TNF-alpha decreased. Dexamethasone 27-30 interleukin 6 Homo sapiens 54-58 18368033-5 2008 The results show that glucocorticoids (dexamethasone, prednisolone, cortisol and corticosterone) caused a concentration-dependent inhibition of LPS-stimulated IL-6 levels. Dexamethasone 39-52 interleukin 6 Homo sapiens 159-163 18719648-7 2008 To study GC-sensitivity in vitro, we performed dose-response studies of DEX-induced suppression of interleukin-6 (IL-6) secretion in skin fibroblast cultures. Dexamethasone 72-75 interleukin 6 Homo sapiens 114-118 18551321-2 2008 We investigated the role of dexamethasone combined with antibiotics in diminishing urinary interleukin-6 (UIL-6) and UIL-8 concentrations during the acute phase of pyelonephritis compared with standard antibiotic therapy. Dexamethasone 28-41 interleukin 6 Homo sapiens 91-104 18314542-6 2008 TNF-alpha-induced IL-6 mRNA decays at a significantly faster rate in ASM cells pretreated with the corticosteroid dexamethasone (t(1/2) = 2.4 h), compared to vehicle (t(1/2) = 9.0 h; P < 0.05) (results are expressed as decay constants [k] [mean +/- SEM] and half-life [h]). Dexamethasone 114-127 interleukin 6 Homo sapiens 18-22 18260364-10 2008 Besides adrenal androgen blockade, dexamethasone suppresses the growth of prostate cancer via NFkappaB inactivation, and also via the inhibition of interleukin-6 production which is reportedly important for the growth of prostate cancer. Dexamethasone 35-48 interleukin 6 Homo sapiens 148-161 18314542-9 2008 Moreover, TNF-alpha acts via a p38 MAPK-dependent pathway to stabilize the IL-6 mRNA transcript (TNF-alpha, t(1/2) = 9.6 h; SB203580 + TNF-alpha, t(1/2) = 1.5 h), exogenous expression of MKP-1 significantly inhibits TNF-alpha-induced IL-6 secretion and MKP-1 siRNA reverses the inhibition of TNF-alpha-induced IL-6 secretion by dexamethasone. Dexamethasone 328-341 interleukin 6 Homo sapiens 75-79 18356656-11 2008 A single dose of dexamethasone reduces IL-6 and PNE levels associated with CPB. Dexamethasone 17-30 interleukin 6 Homo sapiens 39-43 17664049-4 2008 The CSF2 IL-6 levels of patients with/without dexamethasone were significantly lower than for CSF1 IL-6 levels (p = 0.0077, and p = 0.0431, respectively). Dexamethasone 46-59 interleukin 6 Homo sapiens 9-13 18468809-5 2008 GR sensitivity to dexamethasone was evaluated through IL-6 inhibition in stimulated whole blood. Dexamethasone 18-31 interleukin 6 Homo sapiens 54-58 18181043-11 2008 Intracellular IL-6, as well as IL-6 in the conditioned medium, decreased in OUR-10 cells following treatment with increasing amounts of DEX. Dexamethasone 136-139 interleukin 6 Homo sapiens 14-18 18181043-11 2008 Intracellular IL-6, as well as IL-6 in the conditioned medium, decreased in OUR-10 cells following treatment with increasing amounts of DEX. Dexamethasone 136-139 interleukin 6 Homo sapiens 31-35 18181043-13 2008 CONCLUSION: DEX treatment is a candidate for advanced RCC therapy by inhibiting the activation of NF-kappa B and its downstream products such as IL-6, IL-8 and VEGF. Dexamethasone 12-15 interleukin 6 Homo sapiens 145-149 19206545-7 2008 Furthermore, at 4 nm thick per layer, orders of magnitude thinner than conventional drug delivery coatings, these dexamethasone-copolymer mixtures (PolyDex) suppressed in vitro expression of the inflammatory cytokines/signaling elements interleukin 6 (IL-6), interleukin 12 (IL-12), tumor necrosis factor alpha (TNFalpha), inducible nitric oxide synthase (iNOS), and interferon gamma inducible protein (IP-10). Dexamethasone 114-127 interleukin 6 Homo sapiens 237-250 19206545-7 2008 Furthermore, at 4 nm thick per layer, orders of magnitude thinner than conventional drug delivery coatings, these dexamethasone-copolymer mixtures (PolyDex) suppressed in vitro expression of the inflammatory cytokines/signaling elements interleukin 6 (IL-6), interleukin 12 (IL-12), tumor necrosis factor alpha (TNFalpha), inducible nitric oxide synthase (iNOS), and interferon gamma inducible protein (IP-10). Dexamethasone 114-127 interleukin 6 Homo sapiens 252-256 18668392-8 2008 Dexamethasone enhanced IL-10 (p = 0.013) and suppressed IL-1beta, TNF-alpha, interleukin 6 (IL-6), and interleukin 8 (IL-8) (p = 0.013). Dexamethasone 0-13 interleukin 6 Homo sapiens 77-90 18668392-8 2008 Dexamethasone enhanced IL-10 (p = 0.013) and suppressed IL-1beta, TNF-alpha, interleukin 6 (IL-6), and interleukin 8 (IL-8) (p = 0.013). Dexamethasone 0-13 interleukin 6 Homo sapiens 92-96 18158367-6 2008 GC sensitivity was measured by dexamethasone inhibition of lipopolysaccharide-induced interleukin-6 and tumor necrosis factor-alpha production in whole blood. Dexamethasone 31-44 interleukin 6 Homo sapiens 86-131 17891168-10 2007 The anti-inflammatory glucocorticoid, dexamethasone, inhibited the histamine enhanced NF-kappaB-dependent transcription and IL-6 and IL-8 release. Dexamethasone 38-51 interleukin 6 Homo sapiens 124-128 17644731-3 2007 Growth and survival cytokines such as interleukin-6 (IL-6) and insulin-like growth factor-I (IGF-I), which could protect myeloma cells from dexamethasone-induced apoptosis, did not affect mAb-mediated cell death. Dexamethasone 140-153 interleukin 6 Homo sapiens 38-51 17686057-6 2007 It was further demonstrated that IL-6-induced activation of SPHK inhibited dexamethasone-induced apoptosis of MM cells. Dexamethasone 75-88 interleukin 6 Homo sapiens 33-37 17628646-8 2007 Dexamethasone treatment of BECs only partially suppressed IP-10 and TNF-alpha but was more effective at suppressing RANTES, IL-6, and IL-8. Dexamethasone 0-13 interleukin 6 Homo sapiens 124-128 17289483-10 2007 DEX significantly reduced at least 1 postoperative level of IL-6, IL-8, IL-10, CRP, and exhaled NO. Dexamethasone 0-3 interleukin 6 Homo sapiens 60-64 16857895-0 2006 High dexamethasone concentration prevents stimulatory effects of TNF-alpha and LPS on IL-6 secretion from the precursors of human muscle regeneration. Dexamethasone 5-18 interleukin 6 Homo sapiens 86-90 16857895-8 2006 Dex, applied at the 0.1-100 nM concentration range, prevented constitutive and TNF-alpha- and LPS-stimulated IL-6 release at both developmental stages but only at high concentration (P < 0.01). Dexamethasone 0-3 interleukin 6 Homo sapiens 109-113 17161616-11 2006 Several pro-inflammatory/resorptive cytokines including IL-6, IL-4, IFN-gamma, macrophage inhibitory factor (MIF) were down-regulated not only by DEX but also by DHEA. Dexamethasone 146-149 interleukin 6 Homo sapiens 56-60 17077666-7 2006 In contrast, Dex treatment inhibited the IL-1beta-induced production of GM-CSF, IL-6, IL-8, MCP-3, and RANTES, but not MCP-1. Dexamethasone 13-16 interleukin 6 Homo sapiens 80-84 16936090-6 2006 Triptolide and dexamethasone each inhibited in a concentration-dependent manner the LPS-induced release of IL-6, G-CSF, MCP-1, and IL-8 by corneal fibroblasts. Dexamethasone 15-28 interleukin 6 Homo sapiens 107-111 16936090-7 2006 Whereas the inhibitory effect of dexamethasone on LPS-induced IL-6 release was greater than that of triptolide, the inhibitory effect of triptolide on LPS-induced G-CSF release was more pronounced than was that of dexamethasone. Dexamethasone 33-46 interleukin 6 Homo sapiens 62-66 16954997-3 2006 Because glucocorticoids modulate the bone turnover and inhibit inflammatory processes, we investigated the effect of dexamethasone (Dex) on interleukin-6 and DTDST in otosclerosis. Dexamethasone 117-130 interleukin 6 Homo sapiens 140-153 16954997-3 2006 Because glucocorticoids modulate the bone turnover and inhibit inflammatory processes, we investigated the effect of dexamethasone (Dex) on interleukin-6 and DTDST in otosclerosis. Dexamethasone 132-135 interleukin 6 Homo sapiens 140-153 16887032-13 2006 However, later stage pathological consequences of Abeta treatment associated with inflammation and cell degeneration including increased levels of IL-6, activation of MMP-2, and loss of HCSM alpha actin were significantly diminished by dexamethasone but not by indomethacin or ibuprofen. Dexamethasone 236-249 interleukin 6 Homo sapiens 147-151 16614347-6 2006 LPS-induced release of 10 cytokines was less suppressed by dexamethasone (10(-6) M) in patients with severe asthma compared with patients with nonsevere asthma, with statistical significance achieved for IL-1beta (p < 0.03), IL-8 (p < 0.03), and MIP-1alpha (p < 0.003), and borderline significance for IL-6 (p = 0.054). Dexamethasone 59-72 interleukin 6 Homo sapiens 311-315 16954997-13 2006 Interleukin (IL)-6 stimulated DTDST activity in normal stapes, whereas Dex inhibited IL-6 production only in otosclerotic stapes. Dexamethasone 71-74 interleukin 6 Homo sapiens 85-89 16954997-14 2006 CONCLUSION: Dex inhibits the DTDST activity, at least in part, through a reduction of IL-6 secretion only in otosclerotic cells. Dexamethasone 12-15 interleukin 6 Homo sapiens 86-90 16896803-6 2006 In HCAEC exposed to TNF-alpha, IVIG and dexamethasone inhibited interleukin-6 production to a similar degree, whereas the expression of E-selectin was inhibited more strongly by IVIG. Dexamethasone 40-53 interleukin 6 Homo sapiens 64-77 16461744-3 2006 Functional studies revealed that dexamethasone (DEX) inhibited phorbol 12-myristate 13-acetate/ionomycin-induced tumor necrosis factor alpha and interleukin-6 production to a significantly lesser extent in monocytes than T cells. Dexamethasone 33-46 interleukin 6 Homo sapiens 145-158 16524883-6 2006 Dexamethasone potentiated IL-6 induction of the gammaFBG promoter 2.3-fold in both HepG2 and A549 cells for a combined increase in promoter activity of 70-fold or 4.5-fold, respectively. Dexamethasone 0-13 interleukin 6 Homo sapiens 26-30 16524883-7 2006 Dexamethasone potentiation is likely due to the induction of IL-6-receptor expression as well as prolonged intensity and duration of Stat3 activation. Dexamethasone 0-13 interleukin 6 Homo sapiens 61-65 16461744-3 2006 Functional studies revealed that dexamethasone (DEX) inhibited phorbol 12-myristate 13-acetate/ionomycin-induced tumor necrosis factor alpha and interleukin-6 production to a significantly lesser extent in monocytes than T cells. Dexamethasone 48-51 interleukin 6 Homo sapiens 145-158 16476030-5 2006 RESULTS: Following the dexamethasone treatment, the levels of TNF-alpha, IL-1-alpha, IL-6, and IL-8 were decreased significantly, and IL-1-alpha and IL-8 were detected at a level without a statistically significant difference from controls. Dexamethasone 23-36 interleukin 6 Homo sapiens 85-89 29350843-3 2006 Functional studies revealed that dexamethasone (DEX) inhibited phorbol 12-myristate 13-acetate/ionomycin-induced tumor necrosis factor alpha and interleukin-6 production to a significantly lesser extent in monocytes than T cells. Dexamethasone 33-46 interleukin 6 Homo sapiens 145-158 29350843-3 2006 Functional studies revealed that dexamethasone (DEX) inhibited phorbol 12-myristate 13-acetate/ionomycin-induced tumor necrosis factor alpha and interleukin-6 production to a significantly lesser extent in monocytes than T cells. Dexamethasone 48-51 interleukin 6 Homo sapiens 145-158 16278781-4 2005 Our data show that IGF-1, TGF-beta1, bFGF and IL-6 increase PTHrP mRNA expression and its perinuclear localization, while zoledronic acid (50 muM, 100 muM for 24 h and 48 h) and dexamethasone suppress PTHrP expression in PC-3 cells. Dexamethasone 178-191 interleukin 6 Homo sapiens 46-50 16354411-7 2005 Dexamethasone (100 nM) not only inhibited PGE2, PGF(2alpha), IL-6 and IL-8 production but also strongly suppressed the expression of COX-2 mRNA and protein. Dexamethasone 0-13 interleukin 6 Homo sapiens 61-65 16113665-0 2005 Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Dexamethasone 66-79 interleukin 6 Homo sapiens 27-40 16113665-1 2005 Interleukin-6 (IL-6) is a major survival factor for multiple myeloma (MM) cells preventing apoptosis induced by dexamethasone (DEX) or chemotherapy. Dexamethasone 112-125 interleukin 6 Homo sapiens 0-13 16113665-1 2005 Interleukin-6 (IL-6) is a major survival factor for multiple myeloma (MM) cells preventing apoptosis induced by dexamethasone (DEX) or chemotherapy. Dexamethasone 112-125 interleukin 6 Homo sapiens 15-19 16113665-1 2005 Interleukin-6 (IL-6) is a major survival factor for multiple myeloma (MM) cells preventing apoptosis induced by dexamethasone (DEX) or chemotherapy. Dexamethasone 127-130 interleukin 6 Homo sapiens 0-13 16113665-1 2005 Interleukin-6 (IL-6) is a major survival factor for multiple myeloma (MM) cells preventing apoptosis induced by dexamethasone (DEX) or chemotherapy. Dexamethasone 127-130 interleukin 6 Homo sapiens 15-19 16236942-7 2005 RESULTS: Dexamethasone modulated the SIRS with lower proinflammatory (IL-6, IL-8) and higher antiinflammatory (IL-10) IL levels. Dexamethasone 9-22 interleukin 6 Homo sapiens 70-74 16184516-7 2005 IL-10 also synergized with the anti-inflammatory glucocorticoid dexamethasone in the induction of DUSP1 mRNA expression in activated macrophages, as well as in the inhibition of IL-6 and IL-12 production. Dexamethasone 64-77 interleukin 6 Homo sapiens 178-182 16204423-8 2005 This was manifest by disparities in interleukin-6 and tumor necrosis factor-alpha production in the presence of dexamethasone. Dexamethasone 112-125 interleukin 6 Homo sapiens 36-81 16223626-9 2005 This was manifested by increased suppression of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) production by dexamethasone. Dexamethasone 127-140 interleukin 6 Homo sapiens 48-61 15796767-9 2005 The LPS-induced IL-6 production was blocked by the specific p38alphaMAP kinase inhibitor, SB203580, and by the synthetic glucocorticoid, dexamethasone. Dexamethasone 137-150 interleukin 6 Homo sapiens 16-20 16002736-7 2005 Dexamethasone completely blocked the effect of IL-1beta on IL-6 expression. Dexamethasone 0-13 interleukin 6 Homo sapiens 59-63 16009562-8 2005 Only dexamethasone caused an inhibition of IL-6 production. Dexamethasone 5-18 interleukin 6 Homo sapiens 43-47 15802527-6 2005 Although interleukin 6 (IL-6) and insulin-like growth factor-1 (IGF-1) abrogate Dex-induced MM cell cytotoxicity, neither IL-6 nor IGF-1 protects against R-etodolac-induced cytotoxicity in MM cells. Dexamethasone 80-83 interleukin 6 Homo sapiens 9-22 15802527-6 2005 Although interleukin 6 (IL-6) and insulin-like growth factor-1 (IGF-1) abrogate Dex-induced MM cell cytotoxicity, neither IL-6 nor IGF-1 protects against R-etodolac-induced cytotoxicity in MM cells. Dexamethasone 80-83 interleukin 6 Homo sapiens 24-28 16024627-5 2005 In the human multiple myeloma cell line IM-9, an autocrine IL-6 loop exists, which enables the cell to resist the effects of dexamethasone, a common treatment for multiple myeloma. Dexamethasone 125-138 interleukin 6 Homo sapiens 59-63 15930364-9 2005 Taken together, these results indicate that inhibition of IL-6 signaling by Sant7 significantly potentiates the therapeutic action of dexamethasone against multiple myeloma cells, providing the preclinical rationale for clinical trials of Sant7 in combination with dexamethasone to improve patient outcome in multiple myeloma. Dexamethasone 134-147 interleukin 6 Homo sapiens 58-62 15930364-9 2005 Taken together, these results indicate that inhibition of IL-6 signaling by Sant7 significantly potentiates the therapeutic action of dexamethasone against multiple myeloma cells, providing the preclinical rationale for clinical trials of Sant7 in combination with dexamethasone to improve patient outcome in multiple myeloma. Dexamethasone 265-278 interleukin 6 Homo sapiens 58-62 15693092-11 2005 TNF-a induced increases in IL-6, IL-8, and COX-2 mRNA were suppressed by dexamethasone in both fd-FLS and td-FLS. Dexamethasone 73-86 interleukin 6 Homo sapiens 27-31 15630592-5 2005 We show that recombinant glucocorticoid receptor (GR) binds strongly to the AGT gene promoter when nucleoside A is present at -217, and dexamethasone treatment increases the interleukin 6 induced promoter activity of reporter constructs containing nucleoside A at -217. Dexamethasone 136-149 interleukin 6 Homo sapiens 174-187 15253951-8 2004 Inhibition of lipopolysaccharide stimulated IL-6 and TNFalpha release by either glucocorticoid was less pronounced in samples from men than in those from women (IL-6: dexamethasone p = 0.033, hydrocortisone p = 0.029; TNFalpha: dexamethasone p < 0.001, hydrocortisone p = 0.089). Dexamethasone 228-241 interleukin 6 Homo sapiens 44-48 15383370-6 2005 IL-6 treatment alone increased (P < 0.05) lipolysis, but this effect was reduced by the addition of dexamethasone and GH such that IL-6 plus dexamethasone and GH had blunted (P < 0.05) lipolysis compared with IL-6 alone. Dexamethasone 103-116 interleukin 6 Homo sapiens 0-4 15383370-6 2005 IL-6 treatment alone increased (P < 0.05) lipolysis, but this effect was reduced by the addition of dexamethasone and GH such that IL-6 plus dexamethasone and GH had blunted (P < 0.05) lipolysis compared with IL-6 alone. Dexamethasone 103-116 interleukin 6 Homo sapiens 134-138 15383370-6 2005 IL-6 treatment alone increased (P < 0.05) lipolysis, but this effect was reduced by the addition of dexamethasone and GH such that IL-6 plus dexamethasone and GH had blunted (P < 0.05) lipolysis compared with IL-6 alone. Dexamethasone 103-116 interleukin 6 Homo sapiens 134-138 15383370-6 2005 IL-6 treatment alone increased (P < 0.05) lipolysis, but this effect was reduced by the addition of dexamethasone and GH such that IL-6 plus dexamethasone and GH had blunted (P < 0.05) lipolysis compared with IL-6 alone. Dexamethasone 144-157 interleukin 6 Homo sapiens 0-4 15590982-5 2004 Furthermore, 100 nM dexamethasone and 30 ng/ml interleukin (IL)-6 induced SAA3 mRNA by up to 11- and 4.8-fold, respectively, in a time-dependent fashion with significant stimulation observed at concentrations as low as 10 nM dexamethasone and 1 ng/ml IL-6. Dexamethasone 20-33 interleukin 6 Homo sapiens 251-255 16761388-6 2005 The drug has been shown experimentally to inhibit the IL-6-induced proliferation of myeloma cells; it demonstrates synergy with dexamethasone and inhibits angiogenesis. Dexamethasone 128-141 interleukin 6 Homo sapiens 54-58 15476200-10 2004 In addition, dexamethasone augmented IL-1beta-induced up-regulation of MKP-1, and this was associated with inhibition of ERK, JNK, and p38 MAPK phosphorylation and IL-6 expression. Dexamethasone 13-26 interleukin 6 Homo sapiens 164-168 15102517-7 2004 Monocyte glucocorticoid sensitivity was defined as the dexamethasone concentration inhibiting IL-6 release by 50%. Dexamethasone 55-68 interleukin 6 Homo sapiens 94-98 15145616-1 2004 We assessed corticosteroid sensitivity in multiple sclerosis (MS) patients compared to control subjects, using an in vitro assay of dexamethasone (Dex) inhibition of lipopolysaccharide (LPS) stimulated-blood interleukin-6 production. Dexamethasone 132-145 interleukin 6 Homo sapiens 208-221 15145616-2 2004 Significantly higher concentrations of dexamethasone were needed to obtain 50%-inhibition (ID(50)) of in vitro LPS stimulated interleukin (IL)-6 production (28.4 x 10(-7) M) in relapsing-remitting MS (RRMS) patients compared to chronic progressive MS (CPMS) patients (6.2 x 10(-7) M) or compared to controls (3.0 x 10(-7) M). Dexamethasone 39-52 interleukin 6 Homo sapiens 126-144 15094775-5 2004 Moreover, inhibition of CDC34 enzymatic activity abrogates interleukin-6-induced protection against Dex-induced apoptosis. Dexamethasone 100-103 interleukin 6 Homo sapiens 59-72 12900415-9 2003 In the absence of a functional glucocorticoid receptor response element, dexamethasone potentiated IL-6-induced gammaFBG promoter activity 2-fold, requiring promoter-proximal Site I and Site II; the promoter-distal Site III had no effect on dexamethasone potentiation of IL-6-induced promoter activity. Dexamethasone 73-86 interleukin 6 Homo sapiens 99-103 15087402-9 2004 In addition, SGN-40 pretreatment of MM.1S cells blocked the ability of IL-6 to protect against Dex-induced inhibition of DNA synthesis. Dexamethasone 95-98 interleukin 6 Homo sapiens 71-75 15039004-6 2004 Glucocorticoid (GC) sensitivity was measured by dexamethasone (DEX) inhibition of lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) production in whole blood. Dexamethasone 48-61 interleukin 6 Homo sapiens 115-128 15039004-6 2004 Glucocorticoid (GC) sensitivity was measured by dexamethasone (DEX) inhibition of lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) production in whole blood. Dexamethasone 48-61 interleukin 6 Homo sapiens 130-134 15039004-6 2004 Glucocorticoid (GC) sensitivity was measured by dexamethasone (DEX) inhibition of lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) production in whole blood. Dexamethasone 63-66 interleukin 6 Homo sapiens 115-128 15039004-6 2004 Glucocorticoid (GC) sensitivity was measured by dexamethasone (DEX) inhibition of lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) production in whole blood. Dexamethasone 63-66 interleukin 6 Homo sapiens 130-134 15039004-8 2004 Less DEX was required for cytokine suppression in PTSD patients (IL-6: t = -2.82, p =.01; TNF-alpha: t = 5.03, p <.001), reflecting higher GC sensitivity of pro-inflammatory cytokine production. Dexamethasone 5-8 interleukin 6 Homo sapiens 65-69 14585094-8 2003 Dexamethasone strongly inhibited basal IL-6 secretion in all IL-6-producing adenoma cell cultures, whereas the IL-6 inhibitory or stimulatory action of other factors (octreotide, transforming growth factor-beta1, insulin-like growth factor-I, pituitary adenylate cyclase-activating peptide and oestradiol) were heterogeneous in the different adenomas. Dexamethasone 0-13 interleukin 6 Homo sapiens 39-43 14585094-8 2003 Dexamethasone strongly inhibited basal IL-6 secretion in all IL-6-producing adenoma cell cultures, whereas the IL-6 inhibitory or stimulatory action of other factors (octreotide, transforming growth factor-beta1, insulin-like growth factor-I, pituitary adenylate cyclase-activating peptide and oestradiol) were heterogeneous in the different adenomas. Dexamethasone 0-13 interleukin 6 Homo sapiens 61-65 14585094-8 2003 Dexamethasone strongly inhibited basal IL-6 secretion in all IL-6-producing adenoma cell cultures, whereas the IL-6 inhibitory or stimulatory action of other factors (octreotide, transforming growth factor-beta1, insulin-like growth factor-I, pituitary adenylate cyclase-activating peptide and oestradiol) were heterogeneous in the different adenomas. Dexamethasone 0-13 interleukin 6 Homo sapiens 61-65 15070696-8 2004 Strikingly, the combinatorial treatment with rapamycin and dexamethasone suppressed the antiapoptotic effects of exogenously added IGF-I and interleukin 6 (IL-6) as well as their stimulation of p70S6K phosphorylation. Dexamethasone 59-72 interleukin 6 Homo sapiens 141-154 15070696-8 2004 Strikingly, the combinatorial treatment with rapamycin and dexamethasone suppressed the antiapoptotic effects of exogenously added IGF-I and interleukin 6 (IL-6) as well as their stimulation of p70S6K phosphorylation. Dexamethasone 59-72 interleukin 6 Homo sapiens 156-160 14726660-2 2004 Myeloma cells resist Dexamethasone induced apoptosis when exposed to IL-6 or IGF-1, both of which are known to activate several signaling cascades. Dexamethasone 21-34 interleukin 6 Homo sapiens 69-73 14726660-3 2004 For the first time, we show the actual contribution of downstream mediators, i.e., activated STAT factors, independent of the contribution of their upstream signaling pathways, on the proliferation and Dexamethasone rescue effects of IL-6 and IGF-1 in Multiple Myeloma. Dexamethasone 202-215 interleukin 6 Homo sapiens 234-238 14671038-11 2004 Dexamethasone significantly inhibited the cytokine-induced IL-6 protein release in PTC, but not in DTC. Dexamethasone 0-13 interleukin 6 Homo sapiens 59-63 12855565-5 2003 Moreover, AS-Hsp27 overcomes interleukin-6 (IL-6)-mediated protection against Dex-induced apoptosis. Dexamethasone 78-81 interleukin 6 Homo sapiens 29-42 12855565-5 2003 Moreover, AS-Hsp27 overcomes interleukin-6 (IL-6)-mediated protection against Dex-induced apoptosis. Dexamethasone 78-81 interleukin 6 Homo sapiens 44-48 12900415-9 2003 In the absence of a functional glucocorticoid receptor response element, dexamethasone potentiated IL-6-induced gammaFBG promoter activity 2-fold, requiring promoter-proximal Site I and Site II; the promoter-distal Site III had no effect on dexamethasone potentiation of IL-6-induced promoter activity. Dexamethasone 73-86 interleukin 6 Homo sapiens 271-275 12900415-9 2003 In the absence of a functional glucocorticoid receptor response element, dexamethasone potentiated IL-6-induced gammaFBG promoter activity 2-fold, requiring promoter-proximal Site I and Site II; the promoter-distal Site III had no effect on dexamethasone potentiation of IL-6-induced promoter activity. Dexamethasone 241-254 interleukin 6 Homo sapiens 99-103 14557477-8 2003 IL-1alpha and dibutyryl cAMP stimulated and dexamethasone inhibited IL-6 secretion; however, bacterial lipopolysaccharide, forskolin, and cholera toxin had no effect. Dexamethasone 44-57 interleukin 6 Homo sapiens 68-72 26983566-5 2003 GC sensitivity was assessed in vitro by dexamethasone inhibition of lipopolysaccharide-stimulated production of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNC-alpha). Dexamethasone 40-53 interleukin 6 Homo sapiens 112-125 15038780-5 2003 Dexamethasone significantly reduced IL-1 beta, IL-6, COX-2, and MMP-1 expression at high cell density. Dexamethasone 0-13 interleukin 6 Homo sapiens 47-51 26983566-5 2003 GC sensitivity was assessed in vitro by dexamethasone inhibition of lipopolysaccharide-stimulated production of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNC-alpha). Dexamethasone 40-53 interleukin 6 Homo sapiens 127-131 14513800-1 2003 AIM: To study the effects of lipopolysaccharide (LPS), the supernatant of U937 cells stimulated with LPS and dexamethasone on interleukin-6 (IL-6) expression in the synoviocyte from patients with rheumatoid arthritis (RA). Dexamethasone 109-122 interleukin 6 Homo sapiens 126-139 12746834-0 2003 Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6. Dexamethasone 22-35 interleukin 6 Homo sapiens 101-114 12746834-5 2003 Of 8 patients who responded to dexamethasone therapy, 5 had 80% or more decrease in serum interleukin-6 (IL-6). Dexamethasone 31-44 interleukin 6 Homo sapiens 90-103 12746834-5 2003 Of 8 patients who responded to dexamethasone therapy, 5 had 80% or more decrease in serum interleukin-6 (IL-6). Dexamethasone 31-44 interleukin 6 Homo sapiens 105-109 12746834-8 2003 CONCLUSIONS: Significant suppression of serum IL-6, probably through inhibition of androgen-independent activation of androgen receptor, may be one of the mechanisms for the effect of dexamethasone therapy in prostate cancer patients with progressive disease. Dexamethasone 184-197 interleukin 6 Homo sapiens 46-50 12873450-8 2003 Baicalin did not suppress IL-1beta-induced IL-6 and IL-8 production, but dexamethasone, baicalein, and wogonin, significantly suppressed IL-6 and IL-8 production. Dexamethasone 73-86 interleukin 6 Homo sapiens 137-141 12873450-9 2003 Elevation of IL-6 and IL-8 mRNA was not suppressed by baicalin but was significantly suppressed by dexamethasone, baicalein, and wogonin. Dexamethasone 99-112 interleukin 6 Homo sapiens 13-17 12883121-6 2003 Inhibition of IL-6 release was determined by coincubation with increasing concentrations of dexamethasone. Dexamethasone 92-105 interleukin 6 Homo sapiens 14-18 12883121-7 2003 Monocyte glucocorticoid sensitivity was defined as the dexamethasone concentration inhibiting IL-6 release by 50%. Dexamethasone 55-68 interleukin 6 Homo sapiens 94-98 12883121-10 2003 However, in highly exhausted participants, dexamethasone was less able to inhibit IL-6 release (p=.010), and the glucocorticoid sensitivity was lower (p=.003) than in nonexhausted subjects. Dexamethasone 43-56 interleukin 6 Homo sapiens 82-86 14513800-1 2003 AIM: To study the effects of lipopolysaccharide (LPS), the supernatant of U937 cells stimulated with LPS and dexamethasone on interleukin-6 (IL-6) expression in the synoviocyte from patients with rheumatoid arthritis (RA). Dexamethasone 109-122 interleukin 6 Homo sapiens 141-145 14513800-6 2003 Dexamethasone markedly inhibited the protein secretion and mRNA expression of IL-6 in FLS cultured with the supernatant from U937 cell stimulated with LPS. Dexamethasone 0-13 interleukin 6 Homo sapiens 78-82 14513800-9 2003 Dexamethasone can inhibit this increase of the IL-6 expression. Dexamethasone 0-13 interleukin 6 Homo sapiens 47-51 12713584-7 2003 Functional significance of these findings was proven in adhesion assays using fibronectin, laminin, and vitronectin, with interleukin-6 causing significant enhancement of adhesion in all cases, tumor necrosis factor alpha and dexamethasone inducing significant reduction of adhesion to fibronectin and laminin, and interferon-gamma significantly inhibiting adhesion to fibronectin only. Dexamethasone 226-239 interleukin 6 Homo sapiens 122-135 12594059-0 2003 Bradykinin induces interleukin-6 production in human airway smooth muscle cells: modulation by Th2 cytokines and dexamethasone. Dexamethasone 113-126 interleukin 6 Homo sapiens 19-32 12875719-8 2003 The increase in IgG, anti-dsDNA and IL-6 protein levels induced by IL-17 was dose-dependent and could be completely blocked by IL-17 monoclonal antibody mIgG(28) and partially blocked by dexamethasone. Dexamethasone 187-200 interleukin 6 Homo sapiens 36-40 12573295-5 2003 GC sensitivity was assessed by dexamethasone (DEX) inhibition of lipopolysaccharide (LPS) stimulated production of interleukin-6 (IL-6) in whole blood, immediately before, as well as 10 and 60 min after the stress test. Dexamethasone 31-44 interleukin 6 Homo sapiens 115-128 12573295-5 2003 GC sensitivity was assessed by dexamethasone (DEX) inhibition of lipopolysaccharide (LPS) stimulated production of interleukin-6 (IL-6) in whole blood, immediately before, as well as 10 and 60 min after the stress test. Dexamethasone 31-44 interleukin 6 Homo sapiens 130-134 12573295-5 2003 GC sensitivity was assessed by dexamethasone (DEX) inhibition of lipopolysaccharide (LPS) stimulated production of interleukin-6 (IL-6) in whole blood, immediately before, as well as 10 and 60 min after the stress test. Dexamethasone 46-49 interleukin 6 Homo sapiens 115-128 12573295-5 2003 GC sensitivity was assessed by dexamethasone (DEX) inhibition of lipopolysaccharide (LPS) stimulated production of interleukin-6 (IL-6) in whole blood, immediately before, as well as 10 and 60 min after the stress test. Dexamethasone 46-49 interleukin 6 Homo sapiens 130-134 12594059-5 2003 Actinomycin D (a transcription inhibitor), dexamethasone, indomethacin, IL-4, and IL-13 (Th(2) type cytokines) inhibited the expression of IL-6 by BK. Dexamethasone 43-56 interleukin 6 Homo sapiens 139-143 12729473-12 2003 Dexamethasone but not dihydrotestosterone and progesterone decreased IL-6 and PTHrP secretion. Dexamethasone 0-13 interleukin 6 Homo sapiens 69-73 12433870-2 2003 In vitro dexamethasone inhibition of LPS-induced interleukin-6 secretion in cultures of peripheral monocytes was compared in untrained subjects (UT) and in endurance-trained men (ET) at the end of a 2-h run and during exercise recovery. Dexamethasone 9-22 interleukin 6 Homo sapiens 49-62 12581572-13 2003 Correlative data showed a trend towards decreased plasma IL-6 and TNF-alpha after each cycle of therapy presumably due to the dexamethasone premedication and/or paclitaxel. Dexamethasone 126-139 interleukin 6 Homo sapiens 57-61 12483530-10 2002 Protection from dexamethasone-induced apoptosis correlates with IL-6 concentration and Ras activation. Dexamethasone 16-29 interleukin 6 Homo sapiens 64-68 12208756-7 2002 PTK787 enhances the inhibitory effect of dexamethasone on growth of MM cells and can overcome the protective effect of interleukin 6 (IL-6) against dexamethasone-induced apoptosis. Dexamethasone 148-161 interleukin 6 Homo sapiens 119-132 12239628-3 2002 We have investigated whether the IL-6 receptor super-antagonist Sant7 might enhance the antiproliferative and apoptotic effects induced by the combination of dexamethasone (Dex) and zoledronic acid (Zln) on human MM cell lines and primary cells from MM patients. Dexamethasone 158-171 interleukin 6 Homo sapiens 33-37 12239628-3 2002 We have investigated whether the IL-6 receptor super-antagonist Sant7 might enhance the antiproliferative and apoptotic effects induced by the combination of dexamethasone (Dex) and zoledronic acid (Zln) on human MM cell lines and primary cells from MM patients. Dexamethasone 173-176 interleukin 6 Homo sapiens 33-37 12115453-7 2002 Dex reduced the release of NO, VEGF, IL-6, MMP-2, and MMP-9. Dexamethasone 0-3 interleukin 6 Homo sapiens 37-41 12239628-0 2002 The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Dexamethasone 101-114 interleukin 6 Homo sapiens 4-8 12208756-7 2002 PTK787 enhances the inhibitory effect of dexamethasone on growth of MM cells and can overcome the protective effect of interleukin 6 (IL-6) against dexamethasone-induced apoptosis. Dexamethasone 148-161 interleukin 6 Homo sapiens 134-138 12097303-9 2002 Importantly, IGF-1 and IL-6 abrogate Dex-induced down-regulation of telomerase activity and apoptosis. Dexamethasone 37-40 interleukin 6 Homo sapiens 23-27 12173037-6 2002 In contrast, the Akt inhibitor IL-6-Hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate induced cell death of both Dex- and Doxo-sensitive and -resistant cells; opposed the protective effect of constitutive Akt activity against Apo2L/TRAIL; and abrogated the NF-kappaB activation, increase of anti-apoptotic proteins and protection against Apo2L/TRAIL induced by IGF-1. Dexamethasone 132-135 interleukin 6 Homo sapiens 31-35 12173037-1 2002 Interleukin-6 (IL-6) and insulin-like growth factor-1 (IGF-1) promote the proliferation of multiple myeloma (MM) cells and protect them against dexamethasone (Dex)-induced apoptosis. Dexamethasone 144-157 interleukin 6 Homo sapiens 0-13 12173037-1 2002 Interleukin-6 (IL-6) and insulin-like growth factor-1 (IGF-1) promote the proliferation of multiple myeloma (MM) cells and protect them against dexamethasone (Dex)-induced apoptosis. Dexamethasone 144-157 interleukin 6 Homo sapiens 15-19 12173037-1 2002 Interleukin-6 (IL-6) and insulin-like growth factor-1 (IGF-1) promote the proliferation of multiple myeloma (MM) cells and protect them against dexamethasone (Dex)-induced apoptosis. Dexamethasone 159-162 interleukin 6 Homo sapiens 0-13 12173037-1 2002 Interleukin-6 (IL-6) and insulin-like growth factor-1 (IGF-1) promote the proliferation of multiple myeloma (MM) cells and protect them against dexamethasone (Dex)-induced apoptosis. Dexamethasone 159-162 interleukin 6 Homo sapiens 15-19 12080442-7 2002 Dexamethasone decreased IL-6 secretion and increased leptin secretion in a dose-dependent manner. Dexamethasone 0-13 interleukin 6 Homo sapiens 24-28 12080442-9 2002 The effects of dexamethasone and catecholamines on IL-6 and leptin were abrogated by RU486 and propranolol, respectively. Dexamethasone 15-28 interleukin 6 Homo sapiens 51-55 11872748-7 2002 Moreover, PS-1145 blocks the protective effect of IL-6 against Dex-induced apotosis. Dexamethasone 63-66 interleukin 6 Homo sapiens 50-54 11919083-4 2002 TNF-alpha-induced IL-6 secretion was only partially inhibited by dexamethasone, yet TNF-alpha-induced RANTES secretion was abolished. Dexamethasone 65-78 interleukin 6 Homo sapiens 18-22 11768200-7 2001 IL-6 was also able to revert the inhibitory effect of dexamethasone (1 microM) on GR in both cell lines. Dexamethasone 54-67 interleukin 6 Homo sapiens 0-4 11824970-11 2002 IL-6 and IL-10 levels were significantly inhibited by Dex 10 M in both the control and RA groups. Dexamethasone 54-57 interleukin 6 Homo sapiens 0-4 11740818-7 2001 PS-341 adds to the anti-MM activity of dexamethasone and overcomes IL-6-mediated protection against dexamethasone-induced apoptosis. Dexamethasone 100-113 interleukin 6 Homo sapiens 67-71 11717335-3 2001 Because dexamethasone interferes with NF-kappaB activation, we determined whether dexamethasone inhibits prostate cancer growth by working through the glucocorticoid receptor (GR) to interfere with NF-kappaB-IL-6 pathway. Dexamethasone 82-95 interleukin 6 Homo sapiens 208-212 11717335-11 2001 Dexamethasone increased IkappaBalpha protein levels and the cytosolic accumulation of NF-kappaB in DU145 cells and decreased secreted IL-6 levels to 37 pg/mL (95% confidence interval [CI] = 33 pg/mL to 41 pg/mL), compared with 164 pg/mL (95% CI = 162 pg/mL to 166 pg/mL) secreted by ethanol-treated control cells. Dexamethasone 0-13 interleukin 6 Homo sapiens 134-138 11717335-14 2001 CONCLUSION: Dexamethasone inhibited the growth of GR-positive cancers, possibly through the disruption of the NF-kappaB-IL-6 pathway. Dexamethasone 12-25 interleukin 6 Homo sapiens 120-124 11857082-7 2002 In addition, although the level of AKT activation can regulate sensitivity to dexamethasone-induced apoptosis, additional cytokine-induced AKT-independent pathways can mediate IL-6 protection against dexamethasone. Dexamethasone 200-213 interleukin 6 Homo sapiens 176-180 11782767-10 2002 RESULTS: As expected, dexamethasone pretreatment attenuated interleukin 6 release and the clinical systemic inflammatory response after bypass. Dexamethasone 22-35 interleukin 6 Homo sapiens 60-73 11418615-11 2001 We observed that the anti-inflammatory action of PPAR alpha is not restricted to fibrinogen but also applies to other acute phase genes containing a C/EBP response element; it also occurs under conditions in which the stimulating action of IL-6 is potentiated by dexamethasone. Dexamethasone 263-276 interleukin 6 Homo sapiens 240-244 11719636-8 2001 GC sensitivity was assessed in vitro by dexamethasone inhibition of lipopolysaccharide-stimulated production of interleukin-6 and tumor necrosis factor-alpha. Dexamethasone 40-53 interleukin 6 Homo sapiens 112-157 11713366-2 2001 We have here investigated the potential effect of Dex in U1 cells stimulated with interleukin-6 (IL-6), a cytokine inducing virus expression by acting mostly at a post-transcriptional level on the virus life cycle. Dexamethasone 50-53 interleukin 6 Homo sapiens 82-95 11713366-2 2001 We have here investigated the potential effect of Dex in U1 cells stimulated with interleukin-6 (IL-6), a cytokine inducing virus expression by acting mostly at a post-transcriptional level on the virus life cycle. Dexamethasone 50-53 interleukin 6 Homo sapiens 97-101 11713366-9 2001 No substantial HIV RNA accumulation was demonstrated in U1 cells co-stimulated with IL-6 and Dex, whereas IL-6 upregulated the expression of MCP-1 RNA, and this effect was inhibited by Dex. Dexamethasone 185-188 interleukin 6 Homo sapiens 106-110 11713366-10 2001 In contrast, Dex potentiated IL-6 induced activation of AP-1 and ERK1/2 MAPK phosphorylation, as revealed by EMSA. Dexamethasone 13-16 interleukin 6 Homo sapiens 29-33 11593406-2 2001 IL-6 also confers protection against Dexamethasone (Dex)-induced apoptosis via activation of protein tyrosine phosphatase (SHP2). Dexamethasone 37-50 interleukin 6 Homo sapiens 0-4 11593406-2 2001 IL-6 also confers protection against Dexamethasone (Dex)-induced apoptosis via activation of protein tyrosine phosphatase (SHP2). Dexamethasone 37-40 interleukin 6 Homo sapiens 0-4 11593406-7 2001 We demonstrate that Dex-induced apoptosis in MM.1S cells is mediated by downstream activation of caspase-9, with resultant caspase-3 cleavage; and conversely, that IL-6 triggers activation of PI3-K and its association with SHP2, inactivates caspase-9, and protects against Dex-induced apoptosis. Dexamethasone 20-23 interleukin 6 Homo sapiens 164-168 11593406-8 2001 LY294002 completely abrogates this signaling cascade, further confirming the importance of PI3-K/Akt signaling in conferring the protective effect of IL-6 against Dex-induced apoptosis. Dexamethasone 163-166 interleukin 6 Homo sapiens 150-154 11459775-3 2001 We therefore examined the effects of the PPARalpha activator fenofibrate and the GR activator dexamethasone on TNFalpha-stimulated expression of IL-6 and vascular cell adhesion molecule-1 in vascular endothelial cells. Dexamethasone 94-107 interleukin 6 Homo sapiens 145-149 11509812-5 2001 Our results showed that dexamethasone, budesonide and rIL-10 significantly inhibited both IL-6 and TNF-alpha production in the THP-1 cell line stimulated by lipopolysaccharide and Ureaplasma urealyticum antigen. Dexamethasone 24-37 interleukin 6 Homo sapiens 90-94 11544464-11 2001 IL-17 did enhance the production of pro-fibrotic cytokines (IL-6 and IL-11) by fibroblasts, and this was inhibited by dexamethasone. Dexamethasone 118-131 interleukin 6 Homo sapiens 60-64 11459775-4 2001 Both fenofibrate and dexamethasone reduced TNFalpha-induced IL-6 production in human vascular endothelial cells, but only fenofibrate reduced TNFalpha-stimulated vascular cell adhesion molecule-1 expression in these cells. Dexamethasone 21-34 interleukin 6 Homo sapiens 60-64 11459775-6 2001 EMSA demonstrated that both fenofibrate and dexamethasone reduced nuclear factor-kappaB binding to its recognition site on the IL-6 promoter, but only fenofibrate reduced such binding to the vascular cell adhesion molecule-1 promoter. Dexamethasone 44-57 interleukin 6 Homo sapiens 127-131 11285373-8 2001 CONCLUSION: DEX may suppress the production of inflammatory cytokines, such as IL-6 and IL-1beta, but it neither prevents the translocation of NF-kappaB to the nucleus nor induces the synthesis of IkappaB-alpha protein in FLSs stimulated by TNF-alpha. Dexamethasone 12-15 interleukin 6 Homo sapiens 79-83 11283920-10 2001 In vitro exposure of MPC cultures to dexamethasone resulted in the down-regulation of IL-6, G-CSF, and GM-CSF in both normal and myeloma MPC cultures. Dexamethasone 37-50 interleukin 6 Homo sapiens 86-90 11356822-4 2001 Interleukin-6, a growth factor for MM, blocks Dex-induced apoptosis and prevents release of Smac. Dexamethasone 46-49 interleukin 6 Homo sapiens 0-13 11357886-5 2001 Dexamethasone (DEX) inhibited both anti-CD3/CD28 and LPS induced IL-6 production at almost the same concentration. Dexamethasone 0-13 interleukin 6 Homo sapiens 65-69 11357886-5 2001 Dexamethasone (DEX) inhibited both anti-CD3/CD28 and LPS induced IL-6 production at almost the same concentration. Dexamethasone 15-18 interleukin 6 Homo sapiens 65-69 11236942-5 2001 An interleukin-6-dependent myeloma cell line ANBL6 was used and treated with dexamethasone, doxorubicin, and melphalan in the presence of bone marrow stromal cells. Dexamethasone 77-90 interleukin 6 Homo sapiens 3-16 11289656-8 2001 Dexamethasone also inhibited the release of IL-6, IL-8, and PGE2 induced by IL-1beta in both OA and RA fibroblasts. Dexamethasone 0-13 interleukin 6 Homo sapiens 44-48 11154226-9 2001 IL-6-producing MCCs showed minimal spontaneous and dexamethasone-induced apoptosis, whereas a regular amplitude of apoptosis occurred in the IL-6(-) MCCs. Dexamethasone 51-64 interleukin 6 Homo sapiens 0-4 11070335-6 2001 Moreover, DEX reduced the plasma levels of IL-6, TNF-alpha and sTNF-R p75. Dexamethasone 10-13 interleukin 6 Homo sapiens 43-47 11125296-8 2000 Interleukin-6 (IL-6) is known to be an essential survival factor of myeloma cells and to protect them from apoptosis induced by different stimuli (e.g. dexamethasone, CD95, serum starvation, gamma-irradiation). Dexamethasone 152-165 interleukin 6 Homo sapiens 0-13 11125296-8 2000 Interleukin-6 (IL-6) is known to be an essential survival factor of myeloma cells and to protect them from apoptosis induced by different stimuli (e.g. dexamethasone, CD95, serum starvation, gamma-irradiation). Dexamethasone 152-165 interleukin 6 Homo sapiens 15-19 11050000-7 2000 ANBL6 is an IL-6-dependent cell line that is sensitive to dexamethasone (Dex), Dox, and Mel. Dexamethasone 58-71 interleukin 6 Homo sapiens 12-16 11050000-7 2000 ANBL6 is an IL-6-dependent cell line that is sensitive to dexamethasone (Dex), Dox, and Mel. Dexamethasone 73-76 interleukin 6 Homo sapiens 12-16 11048965-4 2000 The anti-inflammatory drug, dexamethasone (1 microM), abolished the production of both IL-6 and IL-8 in gingival fibroblasts challenged with PHT in the presence or absence of IL-1beta. Dexamethasone 28-41 interleukin 6 Homo sapiens 87-91 10880513-0 2000 SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. Dexamethasone 61-74 interleukin 6 Homo sapiens 39-52 11061532-3 2000 For this purpose, dexamethasone inhibition of lipopolysaccharide-induced interleukin-6 and tumor necrosis factor-alpha production in peripheral leukocytes, beclomethasone dipropionate-induced skin blanching, and suppression of cortisol levels after low-dose (0.5 mg) dexamethasone suppression test were determined in each subject. Dexamethasone 18-31 interleukin 6 Homo sapiens 73-118 10880513-1 2000 Our previous studies have shown that activation of a related adhesion focal tyrosine kinase (RAFTK) (also known as Pyk2) is required for dexamethasone (Dex)-induced apoptosis in multiple myeloma (MM) cells and that human interleukin-6 (IL-6), a known growth and survival factor for MM cells, blocks both RAFTK activation and apoptosis induced by Dex. Dexamethasone 137-150 interleukin 6 Homo sapiens 221-234 10880513-1 2000 Our previous studies have shown that activation of a related adhesion focal tyrosine kinase (RAFTK) (also known as Pyk2) is required for dexamethasone (Dex)-induced apoptosis in multiple myeloma (MM) cells and that human interleukin-6 (IL-6), a known growth and survival factor for MM cells, blocks both RAFTK activation and apoptosis induced by Dex. Dexamethasone 137-150 interleukin 6 Homo sapiens 236-240 10880513-1 2000 Our previous studies have shown that activation of a related adhesion focal tyrosine kinase (RAFTK) (also known as Pyk2) is required for dexamethasone (Dex)-induced apoptosis in multiple myeloma (MM) cells and that human interleukin-6 (IL-6), a known growth and survival factor for MM cells, blocks both RAFTK activation and apoptosis induced by Dex. Dexamethasone 152-155 interleukin 6 Homo sapiens 221-234 10880513-1 2000 Our previous studies have shown that activation of a related adhesion focal tyrosine kinase (RAFTK) (also known as Pyk2) is required for dexamethasone (Dex)-induced apoptosis in multiple myeloma (MM) cells and that human interleukin-6 (IL-6), a known growth and survival factor for MM cells, blocks both RAFTK activation and apoptosis induced by Dex. Dexamethasone 152-155 interleukin 6 Homo sapiens 236-240 10880513-1 2000 Our previous studies have shown that activation of a related adhesion focal tyrosine kinase (RAFTK) (also known as Pyk2) is required for dexamethasone (Dex)-induced apoptosis in multiple myeloma (MM) cells and that human interleukin-6 (IL-6), a known growth and survival factor for MM cells, blocks both RAFTK activation and apoptosis induced by Dex. Dexamethasone 346-349 interleukin 6 Homo sapiens 221-234 10880513-1 2000 Our previous studies have shown that activation of a related adhesion focal tyrosine kinase (RAFTK) (also known as Pyk2) is required for dexamethasone (Dex)-induced apoptosis in multiple myeloma (MM) cells and that human interleukin-6 (IL-6), a known growth and survival factor for MM cells, blocks both RAFTK activation and apoptosis induced by Dex. Dexamethasone 346-349 interleukin 6 Homo sapiens 236-240 10880513-2 2000 However, the mechanism whereby IL-6 inhibits Dex-induced apoptosis is undefined. Dexamethasone 45-48 interleukin 6 Homo sapiens 31-35 10880513-4 2000 We show that IL-6 triggers selective activation of SHP2 and its association with RAFTK in Dex-treated MM cells. Dexamethasone 90-93 interleukin 6 Homo sapiens 13-17 10880513-7 2000 Moreover, overexpression of dominant negative SHP2 blocked the protective effect of IL-6 against Dex-induced apoptosis. Dexamethasone 97-100 interleukin 6 Homo sapiens 84-88 10919979-4 2000 These cells produced LBP in response to interleukin (IL)-1beta, IL-6, and tumor necrosis factor- alpha, a response that was strongly enhanced by dexamethasone. Dexamethasone 145-158 interleukin 6 Homo sapiens 64-102 10873159-7 2000 Release of IL-6 elicited by TNF-alpha was significantly inhibited by dexamethasone, cycloheximide, and nordihydroguaiaretic acid (NDGA). Dexamethasone 69-82 interleukin 6 Homo sapiens 11-15 10945640-7 2000 IFN-alpha as well as IL-6 prevented DEX plus alphaIGF-1R-induced apoptosis, and this prevention was blocked by the mitogen-activated protein kinase kinase inhibitor, PD098059, or the phosphatidylinositol 3-kinase inhibitor, wortmannin. Dexamethasone 36-39 interleukin 6 Homo sapiens 21-25 10945640-8 2000 Therefore, both IL-6 and IFN-alpha blocked DEX plus alphaIGF-1R-induced apoptosis through activation of the mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways. Dexamethasone 43-46 interleukin 6 Homo sapiens 16-20 10886221-0 2000 A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Dexamethasone 68-81 interleukin 6 Homo sapiens 22-35 10880263-11 2000 The IL-6 signal pathway is mediated through PTK, NF-kappaB, and also involve PKC, intracellular calcium and sensitive to dexamethasone, but is not related to PKA, G-protein and IL-10. Dexamethasone 121-134 interleukin 6 Homo sapiens 4-8 10619980-2 1999 METHODS: For this purpose, in vitro dexamethasone inhibition of lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) secretion in cultures of peripheral monocytes was compared in 6 untrained subjects (UT) and in 6 endurance-trained (ET) men at 0800 h, 24 h after the end of the last session of exercise (ET men). Dexamethasone 36-49 interleukin 6 Homo sapiens 97-110 10843763-4 2000 Dexamethasone increased the expression of the membrane IL-6R and endogenous sIL6R release, and increased responses to supramaximal but not submaximal IL-6 concentrations. Dexamethasone 0-13 interleukin 6 Homo sapiens 55-59 10881828-5 2000 RESULTS: Dexamethasone caused an eightfold decrease in interleukin-6 levels and a greater than threefold decrease in tumor necrosis factor-alpha levels after CPB (p < 0.05). Dexamethasone 9-22 interleukin 6 Homo sapiens 55-68 10810294-0 2000 Stimulation of endogenous GH and interleukin-6 receptors selectively activates different Jaks and Stats, with a Stat5 specific synergistic effect of dexamethasone. Dexamethasone 149-162 interleukin 6 Homo sapiens 33-46 10810294-13 2000 Thus, our studies suggest that while each cytokine, GH and IL-6, may activate various members of the Jak-Stat pathway in overexpression studies, specific activation of Stat3 by IL-6 and of Jak2 and Stat5 by GH can be observed in HEK293 cells and that in this system the synergistic effect of dexamethasone appears specific for Stat5. Dexamethasone 292-305 interleukin 6 Homo sapiens 59-63 10722595-4 2000 Both the fever and the increased levels of IL-1, TNF, IFN-gamma, IL-2, and IL-6 in supernatant fluids obtained from the SEA-stimulated PBMC were decreased by incubating SEA-PBMC with anisomycin (a protein synthesis inhibitor), aminoguanidine (an inhibitor of inducible nitric oxide synthase [NOS]), or dexamethasone (an inhibitor of NOS). Dexamethasone 302-315 interleukin 6 Homo sapiens 75-79 10926317-6 2000 We have confirmed previous reports of IL-6 production by corticotroph adenoma cells and in addition, demonstrated for the first time that the synthetic glucocorticoid dexamethasone is a potent suppressor of intratumoral IL-6 production. Dexamethasone 167-180 interleukin 6 Homo sapiens 38-42 10926317-6 2000 We have confirmed previous reports of IL-6 production by corticotroph adenoma cells and in addition, demonstrated for the first time that the synthetic glucocorticoid dexamethasone is a potent suppressor of intratumoral IL-6 production. Dexamethasone 167-180 interleukin 6 Homo sapiens 220-224 11155789-7 2000 IL-6 was also able to reverse the inhibitory effect of dexamethasone (1 mumol/l) on GR in both cell lines. Dexamethasone 55-68 interleukin 6 Homo sapiens 0-4 10833370-7 2000 The TNF-alpha-induced secretion of IL-6 was inhibited by dexamethasone. Dexamethasone 57-70 interleukin 6 Homo sapiens 35-39 10741750-10 2000 Finally, both hIL-6 and vIL-6 also maintained viability of serum-starved MH60 and B9 cells and blocked dexamethasone-induced apoptosis of MM.1S human myeloma cells. Dexamethasone 103-116 interleukin 6 Homo sapiens 14-19 10619980-9 1999 After exercise, the inhibitory effect of Dex on LPS-induced IL-6 production was restored in ET and was no longer significantly different from that obtained in UT. Dexamethasone 41-44 interleukin 6 Homo sapiens 60-64 10619980-2 1999 METHODS: For this purpose, in vitro dexamethasone inhibition of lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) secretion in cultures of peripheral monocytes was compared in 6 untrained subjects (UT) and in 6 endurance-trained (ET) men at 0800 h, 24 h after the end of the last session of exercise (ET men). Dexamethasone 36-49 interleukin 6 Homo sapiens 112-116 10619980-8 1999 Moreover, when sensitivity to dexamethasone (Dex) was studied and expressed as the percent inhibition of stimulated IL-6 production with 0.3 microg/ml LPS, at 0800 h the percent inhibition was lower in ET subjects compared to UT (P < 0.01 ET vs. UT men) for each Dex concentration used [10-11-10-8 M]. Dexamethasone 30-43 interleukin 6 Homo sapiens 116-120 10619980-8 1999 Moreover, when sensitivity to dexamethasone (Dex) was studied and expressed as the percent inhibition of stimulated IL-6 production with 0.3 microg/ml LPS, at 0800 h the percent inhibition was lower in ET subjects compared to UT (P < 0.01 ET vs. UT men) for each Dex concentration used [10-11-10-8 M]. Dexamethasone 45-48 interleukin 6 Homo sapiens 116-120 10467228-7 1999 Dexamethasone markedly suppressed basal production of interleukin (IL)-6 and IL-11 and that stimulated by parathyroid hormone (PTH), IL-1alpha, or tumour necrosis factor-alpha in a dose-dependent manner. Dexamethasone 0-13 interleukin 6 Homo sapiens 54-72 10597281-9 1999 Finally, interleukin-6 (IL-6), a known survival factor for MM cells, inhibits both activation of RAFTK and apoptosis of MM.1S cells triggered by Dex. Dexamethasone 145-148 interleukin 6 Homo sapiens 9-22 10597281-9 1999 Finally, interleukin-6 (IL-6), a known survival factor for MM cells, inhibits both activation of RAFTK and apoptosis of MM.1S cells triggered by Dex. Dexamethasone 145-148 interleukin 6 Homo sapiens 24-28 10564544-2 1999 We have shown that the inflammatory cytokines, interleukin-6 (IL-6) and heme-induced HO-1 gene expression, were suppressed by dexamethasone (Dex) in a sustained manner. Dexamethasone 126-139 interleukin 6 Homo sapiens 47-60 10564544-2 1999 We have shown that the inflammatory cytokines, interleukin-6 (IL-6) and heme-induced HO-1 gene expression, were suppressed by dexamethasone (Dex) in a sustained manner. Dexamethasone 126-139 interleukin 6 Homo sapiens 62-66 10564544-2 1999 We have shown that the inflammatory cytokines, interleukin-6 (IL-6) and heme-induced HO-1 gene expression, were suppressed by dexamethasone (Dex) in a sustained manner. Dexamethasone 141-144 interleukin 6 Homo sapiens 47-60 10564544-2 1999 We have shown that the inflammatory cytokines, interleukin-6 (IL-6) and heme-induced HO-1 gene expression, were suppressed by dexamethasone (Dex) in a sustained manner. Dexamethasone 141-144 interleukin 6 Homo sapiens 62-66 10564544-6 1999 Although Dex failed to inhibit heme-mediated HO-1 mRNA and HO activity, it was able to reverse IL-6-stimulated HO activity. Dexamethasone 9-12 interleukin 6 Homo sapiens 95-99 10467228-9 1999 As both basal and PTH-stimulated production of IL-6 and IL-11 are decreased by dexamethasone, the increased bone resorption observed in glucocorticoid-induced osteopenia does not appear to be mediated by IL-6 or IL-11. Dexamethasone 79-92 interleukin 6 Homo sapiens 47-51 10086739-4 1999 Moreover, we found IFN-alpha as well as IL-6 can significantly suppress dexamethasone-induced apoptosis. Dexamethasone 72-85 interleukin 6 Homo sapiens 40-44 10511209-9 1999 DEX caused dose-dependent inhibition of IL-1-induced IL-6 mRNA expression, while CSA potentiated IL-1-induced OF IL-6 mRNA expression. Dexamethasone 0-3 interleukin 6 Homo sapiens 53-57 10511209-11 1999 DEX is a potent inhibitor of OF IL-6 mRNA while CSA increases IL-1-induced OF IL-6 gene expression. Dexamethasone 0-3 interleukin 6 Homo sapiens 32-36 10443688-9 1999 Pretreatment with TNFalpha diminished, and with IL-10 improved, the ability of dexamethasone to suppress IL-6 secretion in whole-blood cell cultures (P < 0.01 for both) and to enhance IL-1 receptor antagonist secretion by U937 cells (P < 0.05 for both). Dexamethasone 79-92 interleukin 6 Homo sapiens 105-109 10389698-7 1999 Crohn"s disease patients had a markedly decreased dexamethasone-mediated inhibition of TNF-alpha (P < 0.01), IL-6 (P < 0.001), and IL-1 beta (P < 0.01) compared to healthy subjects, with a shift of the dexamethasone dose-response curve to the right. Dexamethasone 50-63 interleukin 6 Homo sapiens 112-116 10429944-11 1999 Dexamethasone, over a wide range of concentrations, markedly enhanced proteoglycan synthesis and completely reversed the downregulatory effects of IL-1 and IL-6 + sIL-6Ralpha. Dexamethasone 0-13 interleukin 6 Homo sapiens 156-160 10334936-6 1999 We now report that IL-6, a major inducer of acute-phase proteins, stimulates the synthesis and secretion of angiogenin protein in human HepG2 cells within 24 hr following treatment, an effect enhanced by dexamethasone. Dexamethasone 204-217 interleukin 6 Homo sapiens 19-23 10086739-7 1999 However, IL-6-mediated Bcl-X(L) expression is suppressed in the presence of Dex. Dexamethasone 76-79 interleukin 6 Homo sapiens 9-13 9765276-6 1998 IL-17 effects on NO release, as well as iNOS, COX-2, and IL-6 protein expression, were inhibited by the anti-inflammatory drug dexamethasone. Dexamethasone 127-140 interleukin 6 Homo sapiens 57-61 9832618-3 1998 Both synthetic and natural glucocorticoids, i.e., dexamethasone (DEX) and hydrocortisone (HC), respectively, concentration-dependently inhibited protein production and gene expression of IL-6 by human FLSs. Dexamethasone 50-63 interleukin 6 Homo sapiens 187-191 9832618-3 1998 Both synthetic and natural glucocorticoids, i.e., dexamethasone (DEX) and hydrocortisone (HC), respectively, concentration-dependently inhibited protein production and gene expression of IL-6 by human FLSs. Dexamethasone 65-68 interleukin 6 Homo sapiens 187-191 9832618-5 1998 DEX significantly reduced the rate of IL-6 gene transcription without affecting the stability of IL-6 mRNA. Dexamethasone 0-3 interleukin 6 Homo sapiens 38-42 9891500-0 1998 Dexamethasone enhances expression of membrane and soluble interleukin-6 receptors by prostate carcinoma cell lines. Dexamethasone 0-13 interleukin 6 Homo sapiens 58-71 9891500-9 1998 Dexamethasone (Dex)-treatment induced functional IL-6 receptors on DU 145 and PC-3 through upregulation of IL-6R alpha and gpl30. Dexamethasone 0-13 interleukin 6 Homo sapiens 49-53 9891500-9 1998 Dexamethasone (Dex)-treatment induced functional IL-6 receptors on DU 145 and PC-3 through upregulation of IL-6R alpha and gpl30. Dexamethasone 0-3 interleukin 6 Homo sapiens 49-53 10026370-5 1999 Spontaneous secretion of IL-1beta or IL-6 by MC of preterm neonates was less inhibited by dexamethasone as compared with cells from adults. Dexamethasone 90-103 interleukin 6 Homo sapiens 37-41 9794205-13 1998 Expression of several proinflammatory cytokines including TNF-alpha, IL-6, IL-1beta, and IFN-gamma were also elevated in Av-exposed animals and modulated by dexamethasone. Dexamethasone 157-170 interleukin 6 Homo sapiens 69-73 9734662-0 1998 Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells. Dexamethasone 0-13 interleukin 6 Homo sapiens 38-42 9768679-8 1998 DEX treatment also significantly reduced levels of IL-6 and tumor necrosis factor-alpha in culture medium, suggesting that glucocorticoids coordinately reduce cytokine levels in cytotrophoblasts. Dexamethasone 0-3 interleukin 6 Homo sapiens 51-87 9734662-7 1998 Effects of RA + DEX were also least able to be overcome by exogenous IL-6. Dexamethasone 16-19 interleukin 6 Homo sapiens 69-73 9734662-9 1998 Since RPMI 8226 cells have undetectable IL-6, we investigated U266B1 cells and found that RA and DEX decreased both IL-6 secretion and IL-6 RNA levels. Dexamethasone 97-100 interleukin 6 Homo sapiens 40-44 9734662-9 1998 Since RPMI 8226 cells have undetectable IL-6, we investigated U266B1 cells and found that RA and DEX decreased both IL-6 secretion and IL-6 RNA levels. Dexamethasone 97-100 interleukin 6 Homo sapiens 116-120 9734662-9 1998 Since RPMI 8226 cells have undetectable IL-6, we investigated U266B1 cells and found that RA and DEX decreased both IL-6 secretion and IL-6 RNA levels. Dexamethasone 97-100 interleukin 6 Homo sapiens 116-120 9734662-10 1998 Mechanistically, IL-6R down-regulation by RA was enhanced by DEX, whereas IL-6 protein and RNA levels were reduced by DEX and by RA. Dexamethasone 61-64 interleukin 6 Homo sapiens 17-21 9734662-11 1998 In summary, combinations of RA + DEX were not only more effective in inhibiting myeloma cells growth by the dual mechanisms of decreasing proliferative fraction and increasing apoptotic fraction, but were also less able to be overcome by IL-6. Dexamethasone 33-36 interleukin 6 Homo sapiens 238-242 9734662-0 1998 Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells. Dexamethasone 0-13 interleukin 6 Homo sapiens 43-47 9657134-6 1998 These data may explain the palliative efficacy of Dex treatment and provide a rationale for combining IL-6 antagonists with Dex to overcome the IL-6-mediated resistance of immature tumor cells. Dexamethasone 124-127 interleukin 6 Homo sapiens 144-148 9767285-9 1998 The production of IL-1 alpha/IL-6 was inhibited up to 80/89% (10-7-10-6 mol/L before and after irradiation) by dexamethasone in a concentration-dependent manner and with all conditions of incubation. Dexamethasone 111-124 interleukin 6 Homo sapiens 29-33 9639523-1 1998 The mechanism by which interleukin-6 (IL-6) protects multiple myeloma (MM) plasma cells from apoptosis induced by anti-fas antibodies and dexamethasone was studied. Dexamethasone 138-151 interleukin 6 Homo sapiens 23-36 9639523-1 1998 The mechanism by which interleukin-6 (IL-6) protects multiple myeloma (MM) plasma cells from apoptosis induced by anti-fas antibodies and dexamethasone was studied. Dexamethasone 138-151 interleukin 6 Homo sapiens 38-42 9639523-3 1998 However, IL-6-dependent protection of viability correlated with an inhibition of dexamethasone- and anti-fas-induced activation of jun kinase (JNK) and AP-1 transactivation. Dexamethasone 81-94 interleukin 6 Homo sapiens 9-13 9776474-9 1998 In contrast, dexamethasone inhibited markedly the expression of all cytokines tested (IL-2, IL-4, IL-6, IL-10, IFN-gamma and TNF-alpha) in dose-dependent fashion, reducing levels to near to background. Dexamethasone 13-26 interleukin 6 Homo sapiens 98-102 9563797-3 1998 The role of IL-6 in hypercalcemia and bone resorption would suggest that bisphosphonates or dexamethasone could be useful as adjuvant therapy for IL-6 dependent bone metastases which fail to respond to interferon alpha (IFN) alpha 2a and all trans retinoic acid (ATRA). Dexamethasone 92-105 interleukin 6 Homo sapiens 12-16 9563797-3 1998 The role of IL-6 in hypercalcemia and bone resorption would suggest that bisphosphonates or dexamethasone could be useful as adjuvant therapy for IL-6 dependent bone metastases which fail to respond to interferon alpha (IFN) alpha 2a and all trans retinoic acid (ATRA). Dexamethasone 92-105 interleukin 6 Homo sapiens 146-150 9506738-5 1998 Culture of adipose tissue fragments for 7 days with the glucocorticoid dexamethasone markedly suppressed IL-6 production. Dexamethasone 71-84 interleukin 6 Homo sapiens 105-109 9499112-5 1998 Addition of therapeutic concentrations of dexamethasone (1 microM) or ribavirin (90 microg/ml), an antiviral agent, also significantly inhibited the synthesis of IL-6. Dexamethasone 42-55 interleukin 6 Homo sapiens 162-166 9499112-6 1998 Hence, in clinical settings, pharmacological agents such as the specific antagonists of IL-6-inducing cytokines, as well as dexamethasone and ribavirin, could be used to modulate IL-6 production. Dexamethasone 124-137 interleukin 6 Homo sapiens 179-183 9792466-9 1998 Dexa inhibits the constitutive and cytokine stimulated IL-6 expression, whereas there is no in vitro evidence that sex steroids exert a major inhibitory effect on the osteoblastic secretion of IL-6 as demonstrated in a primary human bone cell model. Dexamethasone 0-4 interleukin 6 Homo sapiens 55-59 9537674-4 1998 RESULTS: There was a significant inhibition by dexamethasone (from 1 to 100 nM) on the secretion of monokines (IL-1beta, IL-6, IL-8 and TNF alpha) and lymphokines (IL-2, IL-4, IL-10 and IFN gamma), either after LPS or PHA stimulation (P < 0.01). Dexamethasone 47-60 interleukin 6 Homo sapiens 121-125 9486420-7 1998 In addition, the inhibitory effect of dexamethasone on both IL-6 and TNF-alpha secretion was significantly reduced following exercise, whereas that on IL-10 and IFN-gamma release was not affected. Dexamethasone 38-51 interleukin 6 Homo sapiens 60-64 9505142-5 1998 The upregulation of IL-6 production induced by BK was abolished by the anti-inflammatory agent dexamethasone (DEX) and the phospholipase A2 (PLA2) inhibitor 4-bromphenacyl bromide (BPB). Dexamethasone 95-108 interleukin 6 Homo sapiens 20-24 9505142-5 1998 The upregulation of IL-6 production induced by BK was abolished by the anti-inflammatory agent dexamethasone (DEX) and the phospholipase A2 (PLA2) inhibitor 4-bromphenacyl bromide (BPB). Dexamethasone 110-113 interleukin 6 Homo sapiens 20-24 9802059-10 1998 In the present experiments DEX only slightly decreased the production and secretion of IL-6 by the cells. Dexamethasone 27-30 interleukin 6 Homo sapiens 87-91 9802059-11 1998 The present findings suggest that the slight cytotoxic activity and the drug resistance effects of DEX on PC-3 cells are mediated by induction of lipocortin 1 and inhibition of arachidonic acid metabolism, with no relationship to downregulation of IL-6 levels. Dexamethasone 99-102 interleukin 6 Homo sapiens 248-252 9496264-5 1997 Dexamethasone decreased the IL-1-stimulated IL-6 release in all cases. Dexamethasone 0-13 interleukin 6 Homo sapiens 44-48 9408252-9 1997 Dexamethasone (10 nM) inhibited IL-6/-8 production by approximately 50% throughout the culture period. Dexamethasone 0-13 interleukin 6 Homo sapiens 32-39 9401927-6 1997 Dexamethasone (DEX), a glucocorticoid which is a inhibitor of nuclear factor kappa B (NF-kappa B activation, markedly inhibited IL-1 (alpha or beta) or TNF-alpha-induced IL-6 production; so this production may be partially mediated through NF-kappa B. Dexamethasone 0-13 interleukin 6 Homo sapiens 170-174 9360537-8 1997 However, in combination with IL-6, dexamethasone had a significant additive effect on IL-6 inhibition of CBG secretion and mRNAs in HepG2 cells. Dexamethasone 35-48 interleukin 6 Homo sapiens 86-90 9352014-6 1997 Basal and cytokine-stimulated IL-6 and IL-8 production was inhibited by dexamethasone at concentrations equal to or greater than 1 nM. Dexamethasone 72-85 interleukin 6 Homo sapiens 30-34 9368513-4 1997 The effects of dexamethasone and 17 beta-oestradiol on IL-1-, TNF-, TSH-, forskolin- and phorbol 12-myristate 13-acetate (PMA)-stimulated IL-6 release in serum-free conditions were studied in human thyrocytes derived from patients with Graves" disease and toxic multinodular goitres, and in the immortalised human thyrocyte cell line, HTori3. Dexamethasone 15-28 interleukin 6 Homo sapiens 138-142 9449430-5 1997 The glucocorticoid dexamethasone inhibited the IL-1beta-activated release of IL-6 from the postmortem astrocyte cultures A157 and A295 and from the astroglioma cell lines. Dexamethasone 19-32 interleukin 6 Homo sapiens 77-81 9449430-9 1997 Dexamethasone also inhibited the PGE2 release from the astrocytes and astroglioma cells, however the inhibitory effect of dexamethasone on the IL-1beta-activated IL-6 release could not be prevented by the addition of PGE2. Dexamethasone 122-135 interleukin 6 Homo sapiens 162-166 9401927-6 1997 Dexamethasone (DEX), a glucocorticoid which is a inhibitor of nuclear factor kappa B (NF-kappa B activation, markedly inhibited IL-1 (alpha or beta) or TNF-alpha-induced IL-6 production; so this production may be partially mediated through NF-kappa B. Dexamethasone 15-18 interleukin 6 Homo sapiens 170-174 9252193-1 1997 Alkaline phosphatase, a marker of differentiation in the human alveolar adenocarcinoma cell line A549, is inducible by conditioned medium from lung fibroblasts and by cytokines including oncostatin M and interleukin 6, but only in the presence of a glucocorticoid, dexamethasone. Dexamethasone 265-278 interleukin 6 Homo sapiens 204-217 9368513-5 1997 Dexamethasone inhibited IL-6 production under stimulated conditions. Dexamethasone 0-13 interleukin 6 Homo sapiens 24-28 9368513-8 1997 In Graves" and multinodular goitre thyrocytes, inhibition of IL-1 (100 U/ml)-stimulated IL-6 release by dexamethasone (100 nmol/l) was 62.51% +/- 10.43 (S.E.M. Dexamethasone 104-117 interleukin 6 Homo sapiens 88-92 9185506-5 1997 Administration of dexamethasone to temporal artery-SCID chimeras for 1 wk induced a partial suppression of T cell and macrophage function as indicated by the reduced tissue concentrations of IL-2, IL-1beta, and IL-6 mRNA, and by the diminished expression of inducible NO synthase. Dexamethasone 18-31 interleukin 6 Homo sapiens 211-215 9164976-6 1997 Immunoblot analysis revealed sIL-6R alpha/IL-6- or OM-induced tyrosine phosphorylation of a similar set of proteins in KS cells, and which was augmented significantly in Dex-treated KS cells. Dexamethasone 170-173 interleukin 6 Homo sapiens 30-34 9164976-7 1997 Stimulation of KS cells with sIL-6R alpha/IL-6 or OM induced rapid tyrosine phosphorylation of the transcription factor STAT3, and Dex significantly enhanced the accumulation of tyrosine-phosphorylated STAT3. Dexamethasone 131-134 interleukin 6 Homo sapiens 30-34 9097927-5 1997 Dexamethasone had an enhancing effect on IL-6-induced expression of HP and ACH, but inhibited sPLA2 expression by 50%. Dexamethasone 0-13 interleukin 6 Homo sapiens 41-45 9097927-8 1997 Although dexamethasone potentiated IL-6-induced APP expression in HepG2 cells, it suppressed sPLA2 expression in a dose-dependent manner. Dexamethasone 9-22 interleukin 6 Homo sapiens 35-39 9266970-7 1997 Finally, interleukin-6 (IL-6) inhibits Dex-induced apoptosis, downregulation of MAP and p70S6K growth kinases and PARP cleavage; in contrast, IL-6 does not inhibit IR-induced apoptosis, activation of SAPK/JNK, and PARP cleavage. Dexamethasone 39-42 interleukin 6 Homo sapiens 9-22 9266970-7 1997 Finally, interleukin-6 (IL-6) inhibits Dex-induced apoptosis, downregulation of MAP and p70S6K growth kinases and PARP cleavage; in contrast, IL-6 does not inhibit IR-induced apoptosis, activation of SAPK/JNK, and PARP cleavage. Dexamethasone 39-42 interleukin 6 Homo sapiens 24-28 9224210-2 1997 A coordinated upregulation of A alpha, B beta, and gamma chain FBG gene transcription occurs upon stimulation of A549 lung epithelial cells with dexamethasone (DEX) and the proinflammatory mediator interleukin-6 (IL-6). Dexamethasone 160-163 interleukin 6 Homo sapiens 213-217 9207463-0 1997 Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Dexamethasone 77-90 interleukin 6 Homo sapiens 0-13 9207463-4 1997 Dex induced G1 growth arrest in MM cells, whereas IL-6 facilitated G1 to S phase transition; moreover, the effect of Dex was blocked by IL-6. Dexamethasone 0-3 interleukin 6 Homo sapiens 136-140 9207463-4 1997 Dex induced G1 growth arrest in MM cells, whereas IL-6 facilitated G1 to S phase transition; moreover, the effect of Dex was blocked by IL-6. Dexamethasone 117-120 interleukin 6 Homo sapiens 50-54 9207463-4 1997 Dex induced G1 growth arrest in MM cells, whereas IL-6 facilitated G1 to S phase transition; moreover, the effect of Dex was blocked by IL-6. Dexamethasone 117-120 interleukin 6 Homo sapiens 136-140 9207463-6 1997 Its expression was upregulated by Dex and downregulated by IL-6; again, IL-6 inhibited the increase in p21 triggered by Dex. Dexamethasone 34-37 interleukin 6 Homo sapiens 72-76 9207463-6 1997 Its expression was upregulated by Dex and downregulated by IL-6; again, IL-6 inhibited the increase in p21 triggered by Dex. Dexamethasone 120-123 interleukin 6 Homo sapiens 72-76 9207463-9 1997 Finally, interferon-gamma (IFN-gamma) also induced G1 growth arrest and upregulated p21 protein expression; as with Dex, affects of IFN-gamma were inhibited by IL-6. Dexamethasone 116-119 interleukin 6 Homo sapiens 160-164 9246192-7 1997 As the IL-6 promoter contains multiple binding sites for activated glucocorticoid receptors within the 5" regulatory region, the potential modulation of IL-6 expression by the corticosteroids hydrocortisone, dexamethasone and mometasone furoate was included in our study to modify the radiation-induced stress response. Dexamethasone 208-221 interleukin 6 Homo sapiens 7-11 9246192-7 1997 As the IL-6 promoter contains multiple binding sites for activated glucocorticoid receptors within the 5" regulatory region, the potential modulation of IL-6 expression by the corticosteroids hydrocortisone, dexamethasone and mometasone furoate was included in our study to modify the radiation-induced stress response. Dexamethasone 208-221 interleukin 6 Homo sapiens 153-157 9507569-7 1997 Exposure of cyclosporin A and dexamethasone almost completely inhibited the production of IL-6 and IL-8 after 24 hours of treatment. Dexamethasone 30-43 interleukin 6 Homo sapiens 90-94 8978296-5 1997 Because interleukin-6 (IL-6) is a growth factor for MM cells and inhibits apoptosis induced by dexamethasone and serum starvation, we examined whether IL-6 affects anti-Fas MoAb-induced apoptosis and activation of SAPK or p38 MAPK in MM cells. Dexamethasone 95-108 interleukin 6 Homo sapiens 23-27 8843757-4 1996 There was no difference in either the epinephrine or norepinephrine peaks among the three treatments, but the net area under the curve for IL-6 was smaller after hydrocortisone or dexamethasone than after placebo and smaller after dexamethasone than after hydrocortisone. Dexamethasone 180-193 interleukin 6 Homo sapiens 139-143 8977259-0 1996 Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Dexamethasone 150-163 interleukin 6 Homo sapiens 43-56 9172015-7 1996 Dexamethasone suppressed the LPS-induced expression of mRNA for IL-1 beta and IL-6 in THP-1 cells, whereas the drug never suppressed the mRNA expression for these cytokines in the presence of Y-25510. Dexamethasone 0-13 interleukin 6 Homo sapiens 78-82 8920958-4 1996 The maximal IL-6-induced increase in IGFBP-1 was comparable to that observed with dexamethasone, and this increase was attenuated by diltiazem or dantrolene, both of which are known to reduce the cytosolic Ca2+ concentration. Dexamethasone 82-95 interleukin 6 Homo sapiens 12-16 8923461-4 1996 These act to mediate the action of interleukin-6 and related cytokines to stimulate aromatase expression in the presence of DEX. Dexamethasone 124-127 interleukin 6 Homo sapiens 35-48 8843757-4 1996 There was no difference in either the epinephrine or norepinephrine peaks among the three treatments, but the net area under the curve for IL-6 was smaller after hydrocortisone or dexamethasone than after placebo and smaller after dexamethasone than after hydrocortisone. Dexamethasone 231-244 interleukin 6 Homo sapiens 139-143 8547658-0 1996 Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: synergy through modulation of interleukin-6 autocrine loop at multiple sites. Dexamethasone 37-50 interleukin 6 Homo sapiens 110-123 8651752-11 1996 Fluorescent-activated cell sorter analysis demonstrated that dexamethasone induced a threefold increase in the expression of high-affinity IL-6 receptors. Dexamethasone 61-74 interleukin 6 Homo sapiens 139-143 8651752-13 1996 Dexamethasone exerts a permissive effect on cytokine-mediated increases in transport by increasing IL-6 receptor expression on the cell surface. Dexamethasone 0-13 interleukin 6 Homo sapiens 99-103 8894439-5 1996 In contrast, dexamethasone downregulated IL-6 production by microglial cells and PBMC. Dexamethasone 13-26 interleukin 6 Homo sapiens 41-45 8652179-8 1996 IL-6 production was augmented by the addition of interleukin 1 alpha (IL-1 alpha) in a dose-dependent manner and suppressed by dexamethasone. Dexamethasone 127-140 interleukin 6 Homo sapiens 0-4 9035763-0 1996 [The effect of dexamethasone dose and cell population composition on in vitro production of tumor necrosis factor and interleukin-6 by mononuclear cells in peripheral blood of man]. Dexamethasone 15-28 interleukin 6 Homo sapiens 118-131 8651752-7 1996 Fluorescent-activated cell sorter (FACS) analysis was used to study the effects of dexamethasone on IL-6 receptor number in the well-differentiated human hepatoma HepG2. Dexamethasone 83-96 interleukin 6 Homo sapiens 100-104 8933213-0 1996 Inhibition by dexamethasone of the lipopolysaccharide-induced increase in IL-6 mRNA abundance and IL-6 production in human polymorphonuclear leukocytes. Dexamethasone 14-27 interleukin 6 Homo sapiens 74-78 8933213-0 1996 Inhibition by dexamethasone of the lipopolysaccharide-induced increase in IL-6 mRNA abundance and IL-6 production in human polymorphonuclear leukocytes. Dexamethasone 14-27 interleukin 6 Homo sapiens 98-102 8933213-6 1996 These results indicate that PMNs are an important source of IL-6 in acute inflammatory reactions, and that the anti-inflammatory actions of dexamethasone is attributable in part to inhibition of IL-6 production by these cells. Dexamethasone 140-153 interleukin 6 Homo sapiens 195-199 8728019-3 1996 The synthetic glucocorticoid dexamethasone 1) inhibits the LPS-initiated vascular leak of plasma proteins into the airspace, 2) inhibits the LPS-initiated emigration of neutrophils and lymphocytes into the airspace in a dose-dependent fashion, and 3) inhibits LPS-initiated mRNA and/or bronchoalveolar lavage protein expression of cytokines (TNF, IL-1 and IL-6) and chemokines (MIP-1 alpha, MIP-2 and MCP-1). Dexamethasone 29-42 interleukin 6 Homo sapiens 356-360 8726410-0 1996 Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines. Dexamethasone 70-83 interleukin 6 Homo sapiens 28-32 8726410-3 1996 Previous studies in our laboratory have shown that dexamethasone and suramin inhibit cell proliferation and IL-6-mediated immunoglobulin secretion in various lymphoblastoid and myeloma cell lines. Dexamethasone 51-64 interleukin 6 Homo sapiens 108-112 8726410-4 1996 In the present study, we present study, we present data to examine mechanisms by which dexamethasone and suramin inhibit IL-6-mediated immunoglobulin secretion in the lymphoid cell line SKW 6.4. Dexamethasone 87-100 interleukin 6 Homo sapiens 121-125 8726410-10 1996 An rtPCR analysis of IL-6 mRNA expression shows an abolished signal in response to dexamethasone or rIL-6 and/or dexamethasone. Dexamethasone 83-96 interleukin 6 Homo sapiens 21-25 8726410-10 1996 An rtPCR analysis of IL-6 mRNA expression shows an abolished signal in response to dexamethasone or rIL-6 and/or dexamethasone. Dexamethasone 113-126 interleukin 6 Homo sapiens 21-25 8727677-4 1996 Moreover, BDP was able to reduce the inhibitory effect of a synthetic corticosteroid, dexamethasone on the biosynthesis of IL-6. Dexamethasone 86-99 interleukin 6 Homo sapiens 123-127 8600162-5 1996 Exposure of cells in growth medium to dexamethasone resulted in a decrease in the expression of LIF, IL-6, and IL-11. Dexamethasone 38-51 interleukin 6 Homo sapiens 101-105 8547658-2 1996 We investigated the effect of dexamethasone and all-trans retinoic acid, previously shown to modulate IL-6/IL-6R, on the in vitro growth of a human myeloma cell line, OPM-2. Dexamethasone 30-43 interleukin 6 Homo sapiens 102-106 8547658-7 1996 The effect of dexamethasone but not all-trans retinoic acid was completely reversed by exogenous IL-6. Dexamethasone 14-27 interleukin 6 Homo sapiens 97-101 8547658-11 1996 IL-6 mRNA expression was reduced by dexamethasone and the combination, but was not affected by retinoic acid alone. Dexamethasone 36-49 interleukin 6 Homo sapiens 0-4 8550757-3 1996 To measure corticosteroid sensitivity, we developed an assay based on the inhibition by dexamethasone (Dex) of lipopolysaccharide (LPS)-induced Interleukin-6 (IL-6) production and release in whole unseparated blood in vitro. Dexamethasone 88-101 interleukin 6 Homo sapiens 144-157 8904180-2 1996 Dexamethasone, an inhibitor of cytokine production, inhibited LPS-induced tissue factor and IL-6 release by mononuclear cells (MNC), but enhanced IL-1beta-evoked tissue factor activity. Dexamethasone 0-13 interleukin 6 Homo sapiens 92-96 8536785-7 1996 IL-1 alpha-induced GM-CSF, IL-1 beta, IL-6, IL-11, and LIF mRNA levels were reduced by the addition of dexamethasone, whereas dexamethasone had no influence on the amounts of IL-1 alpha-induced G-CSF mRNA. Dexamethasone 103-116 interleukin 6 Homo sapiens 38-42 8550757-3 1996 To measure corticosteroid sensitivity, we developed an assay based on the inhibition by dexamethasone (Dex) of lipopolysaccharide (LPS)-induced Interleukin-6 (IL-6) production and release in whole unseparated blood in vitro. Dexamethasone 88-101 interleukin 6 Homo sapiens 159-163 8550757-3 1996 To measure corticosteroid sensitivity, we developed an assay based on the inhibition by dexamethasone (Dex) of lipopolysaccharide (LPS)-induced Interleukin-6 (IL-6) production and release in whole unseparated blood in vitro. Dexamethasone 103-106 interleukin 6 Homo sapiens 144-157 8550757-3 1996 To measure corticosteroid sensitivity, we developed an assay based on the inhibition by dexamethasone (Dex) of lipopolysaccharide (LPS)-induced Interleukin-6 (IL-6) production and release in whole unseparated blood in vitro. Dexamethasone 103-106 interleukin 6 Homo sapiens 159-163 8550757-4 1996 LPS induced a dose-dependent increase in IL-6 concentrations up to 34 +/- 6.6 ng/mL, reaching plateau levels after 8 h, whereas Dex dose dependently inhibited LPS-induced IL-6 production. Dexamethasone 128-131 interleukin 6 Homo sapiens 171-175 8550757-5 1996 Involvement of the glucocorticoid receptor in this response was supported by abrogation of Dex (10(-7) mol/L) inhibition of IL-6 production by the glucocorticoid receptor antagonist RU 38486. Dexamethasone 91-94 interleukin 6 Homo sapiens 124-128 8550757-7 1996 Before exercise, 3 x 10(-8) mol/L Dex inhibited LPS-induced IL-6 production in vitro; after exercise, 3 x 10(-8) and 10(-7) mol/L Dex were unable to inhibit IL-6 production. Dexamethasone 34-37 interleukin 6 Homo sapiens 60-64 8550757-8 1996 We conclude that Dex suppression of LPS-induced IL-6 production is an effective means of determining corticosteroid sensitivity, and that corticosteroid sensitivity in human subjects is a dynamic, rather than a static, phenomenon. Dexamethasone 17-20 interleukin 6 Homo sapiens 48-52 7647014-0 1995 The gp 130 family cytokines IL-6, LIF and OSM but not IL-11 can reverse the anti-proliferative effect of dexamethasone on human myeloma cells. Dexamethasone 105-118 interleukin 6 Homo sapiens 28-32 7496871-6 1995 Addition of dexamethasone resulted in a reduction of TNF, IL-1 and IL-6 release to below background levels. Dexamethasone 12-25 interleukin 6 Homo sapiens 67-71 18475705-1 1996 In order to find an explanation for corticosteroid resistance we assessed whether inhibition by dexamethasone (DEX) of the stimulated production of TNF- proportional, variant, IL-6, PGE(2) and LTB(4) by peripheral blood mononuclear cells (MNC) depends on binding to the glucocorticoid receptor (GR), and whether it is determined by the number or the affinity of the GR of these cells. Dexamethasone 96-109 interleukin 6 Homo sapiens 176-180 18475705-1 1996 In order to find an explanation for corticosteroid resistance we assessed whether inhibition by dexamethasone (DEX) of the stimulated production of TNF- proportional, variant, IL-6, PGE(2) and LTB(4) by peripheral blood mononuclear cells (MNC) depends on binding to the glucocorticoid receptor (GR), and whether it is determined by the number or the affinity of the GR of these cells. Dexamethasone 111-114 interleukin 6 Homo sapiens 176-180 18475705-4 1996 DEX caused a concentration dependent inhibition of TNF- proportional, variant, IL-6 and PGE(2) production but had no effect on LTB(4) production. Dexamethasone 0-3 interleukin 6 Homo sapiens 79-83 7647014-6 1995 Therefore the high levels of IL-6 (ng/ml) observed in the MM intermediate milieu and the putative presence of LIF and OSM can easily counteract the effects of dexamethasone in vivo. Dexamethasone 159-172 interleukin 6 Homo sapiens 29-33 7669718-2 1995 There was a higher expression of bcl-XL in cells treated with DEX or DEX plus IL-6 compared to cells treated with IL-6 alone. Dexamethasone 69-72 interleukin 6 Homo sapiens 114-118 7558422-5 1995 A similar inhibitory action of IL-6 was observed on the glucocorticoid dexamethasone (DEX)-induced apo-D and GC-DFP-15 secretion. Dexamethasone 71-84 interleukin 6 Homo sapiens 31-35 7558422-5 1995 A similar inhibitory action of IL-6 was observed on the glucocorticoid dexamethasone (DEX)-induced apo-D and GC-DFP-15 secretion. Dexamethasone 86-89 interleukin 6 Homo sapiens 31-35 7775626-9 1995 To a lesser extent, the combination of interleukin-1, interleukin-6, and tumor necrosis factor-alpha also counteracted the effects of dexamethasone. Dexamethasone 134-147 interleukin 6 Homo sapiens 54-67 7949178-0 1994 Interleukin-6 prevents dexamethasone-induced myeloma cell death. Dexamethasone 23-36 interleukin 6 Homo sapiens 0-13 7743552-7 1995 Addition of IL-6 (but not IL-1 beta, IL-4, IL-7, or IL-10) inhibited PCD of 8226 targets induced by serum starvation or dexamethasone in a concentration-dependent fashion. Dexamethasone 120-133 interleukin 6 Homo sapiens 12-16 7743552-10 1995 Targets protected from PCD by IL-6 were still sensitive to serum starvation and dex-induced cytostasis, but, after reculturing in drug-free complete media, they reinitiated normal proliferation. Dexamethasone 80-83 interleukin 6 Homo sapiens 30-34 7549842-0 1995 Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines. Dexamethasone 0-13 interleukin 6 Homo sapiens 57-70 7549842-5 1995 This study examines growth inhibition and inhibition of IL-6-mediated secretion of immunoglobulin in human lymphoid and myeloma cell lines by dexamethasone and suramin. Dexamethasone 142-155 interleukin 6 Homo sapiens 56-60 7549842-7 1995 IL-6-mediated immunoglobulin secretion is also inhibited by both dexamethasone and suramin in an additive fashion. Dexamethasone 65-78 interleukin 6 Homo sapiens 0-4 7549842-8 1995 Both dexamethasone and suramin induce apoptosis of lymphoid cell lines, and suramin inhibits the binding of IL-6 to its receptor in a multiple myeloma cell line. Dexamethasone 5-18 interleukin 6 Homo sapiens 108-112 7549842-9 1995 These findings suggest that the synergistic growth inhibitory activities of dexamethasone and suramin may be related to induction of apoptosis by both agents and inhibition of IL-6-mediated autocrine growth stimulation and immunoglobulin production. Dexamethasone 76-89 interleukin 6 Homo sapiens 176-180 7482409-8 1995 When combined with either dexamethasone or soluble IL-6 receptor, the IL-6 response was significantly enhanced. Dexamethasone 26-39 interleukin 6 Homo sapiens 70-74 7884317-6 1995 The anti-inflammatory agent, dexamethasone, was the most potent agent in controlling the SE-mediated effects as evidenced by inhibited T cell proliferation (55%) and reduced levels of IL-1, IL-6, and IFN gamma (60% to 100%) and TNF alpha (50%). Dexamethasone 29-42 interleukin 6 Homo sapiens 190-194 7861551-10 1995 A dose-dependent increase in mRNA expression of gp130, the transducer of IL-6 signal, was induced by dexamethasone and progesterone in 2 and 1 of the 4 cell lines, respectively. Dexamethasone 101-114 interleukin 6 Homo sapiens 73-77 7861551-12 1995 Dexamethasone may be useful, not only for palliation of paraneoplastic syndrome caused by overproduction of IL-6, but also for inhibition of growth of renal cell carcinomas. Dexamethasone 0-13 interleukin 6 Homo sapiens 108-112 7695840-6 1994 Dexamethasone had small enhancing effect on the action of IL-6. Dexamethasone 0-13 interleukin 6 Homo sapiens 58-62 7949178-3 1994 Dexamethasone (Dex) concentrations of 10(-7) to 10(-6) mol/L inhibited IL-6 gene expression in three of four cell lines studied, whereas the higher concentration of the hormone inhibited also IL-6R gene expression. Dexamethasone 0-13 interleukin 6 Homo sapiens 71-75 7949178-3 1994 Dexamethasone (Dex) concentrations of 10(-7) to 10(-6) mol/L inhibited IL-6 gene expression in three of four cell lines studied, whereas the higher concentration of the hormone inhibited also IL-6R gene expression. Dexamethasone 0-3 interleukin 6 Homo sapiens 71-75 7949178-5 1994 Dex treatment resulted in killing of sensitive cells associated with DNA fragmentation, which could be reversed by concomitant treatment with IL-6. Dexamethasone 0-3 interleukin 6 Homo sapiens 142-146 7949178-6 1994 The reversal of Dex-mediated effects by IL-6 did not result from an inhibition of GR function as measured by receptor nuclear translocation or Dex-regulated reporter gene function. Dexamethasone 16-19 interleukin 6 Homo sapiens 40-44 7949178-7 1994 These results indicate that blockage of the IL-6 signaling pathway is essential for effective myeloma cell kill by Dex. Dexamethasone 115-118 interleukin 6 Homo sapiens 44-48 8055910-3 1994 To find a possible activity of IL-6 on these cells, a cDNA library of IL-6- and dexamethasone-treated cells was screened with cDNA probes from both induced and non-induced cells. Dexamethasone 80-93 interleukin 6 Homo sapiens 31-35 7947352-5 1994 Specifically, RU486 (at concentrations of 1-100 nM) exerts pure antagonist actions by almost completely reversing the inhibitory effects of the glucocorticoid dexamethasone (Dex) on the release of monocyte/macrophages-derived lymphokines, such as IL-1, IL-6, IL-8 and tumor necrosis factor-alpha (TNF-alpha). Dexamethasone 159-172 interleukin 6 Homo sapiens 253-257 7947352-5 1994 Specifically, RU486 (at concentrations of 1-100 nM) exerts pure antagonist actions by almost completely reversing the inhibitory effects of the glucocorticoid dexamethasone (Dex) on the release of monocyte/macrophages-derived lymphokines, such as IL-1, IL-6, IL-8 and tumor necrosis factor-alpha (TNF-alpha). Dexamethasone 174-177 interleukin 6 Homo sapiens 253-257 7947352-6 1994 Dex decreased in a dose-dependent manner the release of the above four lymphokines, with an ID50 of 0.9 +/- 0.1, 4.76 +/- 0.4, 9.8 +/- 1.8, and 1.16 +/- 0.2 nM for IL-1, IL-6, IL-8 and TNF-alpha, respectively. Dexamethasone 0-3 interleukin 6 Homo sapiens 170-174 7519403-3 1994 Dexamethasone blocks the induction of IL-6 and IL-8 by IL-1 or TNF. Dexamethasone 0-13 interleukin 6 Homo sapiens 38-42 7519403-4 1994 In these studies, we determined whether dexamethasone interferes with the upregulation of IL-6 and IL-8 by downregulating expression of the IL-1 or TNF receptor genes. Dexamethasone 40-53 interleukin 6 Homo sapiens 90-94 7519403-7 1994 Both IL-1 and TNF increased release of IL-6 and IL-8 from the cells in a dose-dependent manner and dexamethasone inhibited this effect. Dexamethasone 99-112 interleukin 6 Homo sapiens 39-43 7519403-8 1994 Dexamethasone also inhibited the induction of IL-6 and IL-8 RNA by IL-1 and TNF. Dexamethasone 0-13 interleukin 6 Homo sapiens 46-50 8004813-6 1994 Dexamethasone suppressed both gene expression and protein production of GM-CSF, IL-6 and IL-8 when fibroblasts were exposed to IL-1 alpha. Dexamethasone 0-13 interleukin 6 Homo sapiens 80-84 7516173-6 1994 A greater than 95% decrease in IL-6 production was seen with 10(-6) and 10(-7) M dexamethasone, prednisolone, and hydrocortisone, and IC50 values for these agents were approximately 5 x 10(-10), 5 x 10(-9), and 10(-8) M, respectively. Dexamethasone 81-94 interleukin 6 Homo sapiens 31-35 7516173-9 1994 However, the magnitude of this effect could not fully account for the potency of the glucocorticoid-induced alterations in IL-6 mRNA accumulation and protein production since 10(-6) M dexamethasone caused only a 50% decrease in IL-1-induced IL-6 gene transcription. Dexamethasone 184-197 interleukin 6 Homo sapiens 241-245 8195587-7 1994 The effect of IL-6 was potentiated by dexamethasone, while an inhibition on HP mRNA inducibility could be prevented by lowering the foetal calf serum (FCS) concentration to 1%. Dexamethasone 38-51 interleukin 6 Homo sapiens 14-18 11271305-5 1994 Dexamethazone, cyclosporin (CyA), and FK 506 at immunosuppressive concentrations induced a dose-dependent inhibition of IL-6 secretion from adherent monocytes (MO) stimulated with phytohemagglutinin (PHA). Dexamethasone 0-13 interleukin 6 Homo sapiens 120-124 8159722-10 1994 In addition, cultured smooth muscle cells expressed SAA1, SAA2, and SAA4 mRNAs when treated with interleukin 1 or 6 (IL-1 or IL-6) in the presence of dexamethasone. Dexamethasone 150-163 interleukin 6 Homo sapiens 125-129 8122626-0 1994 Dexamethasone inhibits production of interleukin-6 by cultured cardiac myxoma cells. Dexamethasone 0-13 interleukin 6 Homo sapiens 37-50 8290595-4 1994 We report that, in intact cells, activation of the interleukin 6 promoter by a combination of the factor NF-IL6 and the p65 subunit of NF-kappa B is inhibited by dexamethasone (ligand)-activated glucocorticoid receptor. Dexamethasone 162-175 interleukin 6 Homo sapiens 51-64 11271305-6 1994 Dexamethazone was the most effective agent in inhibiting IL-6 secretion, while the inhibitory effect observed with 1 ng/ml FK 506 was comparable with that obtained with 100 ng/ml CyA. Dexamethasone 0-13 interleukin 6 Homo sapiens 57-61 8344757-12 1993 Dexamethasone suppressed the release of IL-6, but had no inhibitory effect on IL-10 secretion. Dexamethasone 0-13 interleukin 6 Homo sapiens 40-44 7694480-3 1993 In particular, we assessed whether dexamethasone was capable of inhibiting the tumor necrosis factor-alpha (TNF-alpha)-mediated secretion of interleukin-6 (IL-6), interleukin-8 (IL-8), and granulocyte colony-stimulating factor (G-CSF) by a human bronchial epithelial cell line (BEAS-2B). Dexamethasone 35-48 interleukin 6 Homo sapiens 141-154 7694480-3 1993 In particular, we assessed whether dexamethasone was capable of inhibiting the tumor necrosis factor-alpha (TNF-alpha)-mediated secretion of interleukin-6 (IL-6), interleukin-8 (IL-8), and granulocyte colony-stimulating factor (G-CSF) by a human bronchial epithelial cell line (BEAS-2B). Dexamethasone 35-48 interleukin 6 Homo sapiens 156-160 7694480-6 1993 Dexamethasone preconditioning significantly inhibited both the secretion of immunoreactive IL-6 and the accumulation of IL-6 mRNA. Dexamethasone 0-13 interleukin 6 Homo sapiens 91-95 7694480-6 1993 Dexamethasone preconditioning significantly inhibited both the secretion of immunoreactive IL-6 and the accumulation of IL-6 mRNA. Dexamethasone 0-13 interleukin 6 Homo sapiens 120-124 8429822-8 1993 DEX was also found to be a potent inhibitor of IL-1-induced expression of the IL-6 gene in connective tissue-type cells from the synovium of patients with rheumatoid arthritis. Dexamethasone 0-3 interleukin 6 Homo sapiens 78-82 8096510-3 1993 Dexamethasone strengthened the stimulation by IL-6. Dexamethasone 0-13 interleukin 6 Homo sapiens 46-50 8440709-10 1993 Evidence is presented that the 80-kDa IL-6 receptor up-regulation by PMA-dexamethasone is caused by the depletion of protein kinase C since the protein kinase C inhibitor staurosporine mimics the effect of PMA-dexamethasone. Dexamethasone 73-86 interleukin 6 Homo sapiens 38-42 1544406-0 1992 Up-regulation of the interleukin-6-signal transducing protein (gp130) by interleukin-6 and dexamethasone in HepG2 cells. Dexamethasone 91-104 interleukin 6 Homo sapiens 21-34 1431212-0 1992 Cytokine-stimulated human dermal microvascular endothelial cells produce interleukin 6--inhibition by hydrocortisone, dexamethasone, and calcitriol. Dexamethasone 118-131 interleukin 6 Homo sapiens 73-86 1431212-6 1992 Both hydrocortisone and dexamethasone dose-dependently inhibited the cytokine-induced IL-6 production, whereas the inhibition by calcitriol was less pronounced. Dexamethasone 24-37 interleukin 6 Homo sapiens 86-90 1485590-3 1992 There was a dose-dependent decrease in the number of colonies formed in vitro of NC65 renal cell carcinoma cell line in the presence of dexamethasone which is known to inhibit the induction of IL-6 messenger RNA. Dexamethasone 136-149 interleukin 6 Homo sapiens 193-197 1384466-10 1992 Expression of IL-6 receptor mRNA was not up-regulated by cytokines, but only by 1 microM-dexamethasone. Dexamethasone 89-102 interleukin 6 Homo sapiens 14-18 1630586-5 1992 As reported previously, 10(-13) M IL-6 increased CRF release, which was significantly suppressed by DEX in a dose-dependent manner. Dexamethasone 100-103 interleukin 6 Homo sapiens 34-38 1630586-7 1992 The response to IL-6 was completely blocked at the highest DEX concentration evaluated (10(-5) M). Dexamethasone 59-62 interleukin 6 Homo sapiens 16-20 1550404-10 1992 In contrast, dexamethasone (10(-6) mol/l) suppressed the ability of IL-1 to increase the expression of IL-6 mRNA. Dexamethasone 13-26 interleukin 6 Homo sapiens 103-107 1370208-4 1992 Dexamethasone (1 mumol/L) concordantly repressed expression of GM-CSF, NAP-1/IL-8 and IL-6. Dexamethasone 0-13 interleukin 6 Homo sapiens 86-90 19912845-4 1992 During short-term incubations of U87MG cells (6 h) in the presence of IL 1beta and dexamethasone (DEX), DEX inhibited IL 1beta-stimulated IL 6 production over the entire range of the dose-response curve. Dexamethasone 83-96 interleukin 6 Homo sapiens 138-142 19912845-4 1992 During short-term incubations of U87MG cells (6 h) in the presence of IL 1beta and dexamethasone (DEX), DEX inhibited IL 1beta-stimulated IL 6 production over the entire range of the dose-response curve. Dexamethasone 98-101 interleukin 6 Homo sapiens 138-142 19912845-4 1992 During short-term incubations of U87MG cells (6 h) in the presence of IL 1beta and dexamethasone (DEX), DEX inhibited IL 1beta-stimulated IL 6 production over the entire range of the dose-response curve. Dexamethasone 104-107 interleukin 6 Homo sapiens 138-142 19912845-5 1992 However, when cells were preincubated in the presence of DEX for 15 h and then challenged with IL 1beta or IL 1beta and DEX, there was a left-shift in the IL 1,B dose-response curve, suggesting an increased sensitivity of the cells to respond to IL 1 and produce IL 6. Dexamethasone 57-60 interleukin 6 Homo sapiens 263-267 19912845-5 1992 However, when cells were preincubated in the presence of DEX for 15 h and then challenged with IL 1beta or IL 1beta and DEX, there was a left-shift in the IL 1,B dose-response curve, suggesting an increased sensitivity of the cells to respond to IL 1 and produce IL 6. Dexamethasone 120-123 interleukin 6 Homo sapiens 263-267 19912845-6 1992 In fact, the ED(50) for IL 1beta-stimulated IL 6 production was about 1.3 pM in cells not preincubated with DEX, but was reduced to 0.25 pM in cells that were preincubated with DEX. Dexamethasone 108-111 interleukin 6 Homo sapiens 44-48 19912845-6 1992 In fact, the ED(50) for IL 1beta-stimulated IL 6 production was about 1.3 pM in cells not preincubated with DEX, but was reduced to 0.25 pM in cells that were preincubated with DEX. Dexamethasone 177-180 interleukin 6 Homo sapiens 44-48 19912845-7 1992 However, maximum IL 6 production at high doses of IL 1beta was inhibited in cells cultured in the presence of DEX during the IL 1 challenge. Dexamethasone 110-113 interleukin 6 Homo sapiens 17-21 1370208-9 1992 Further experiments showed that dexamethasone downregulates expression of GM-CSF, NAP-1/IL-8, and IL-6 mainly by decreasing the mRNA stability of these cytokines, and that the dexamethasone-mediated repression of cytokine expression depends on ongoing protein and RNA syntheses. Dexamethasone 32-45 interleukin 6 Homo sapiens 98-102 1370208-9 1992 Further experiments showed that dexamethasone downregulates expression of GM-CSF, NAP-1/IL-8, and IL-6 mainly by decreasing the mRNA stability of these cytokines, and that the dexamethasone-mediated repression of cytokine expression depends on ongoing protein and RNA syntheses. Dexamethasone 176-189 interleukin 6 Homo sapiens 98-102 1699862-7 1990 Although the synthetic glucocorticoid dexamethasone slightly modulated the effect of recombinant interleukin-6, it was not an absolute requirement for the induction of acute-phase protein synthesis in human hepatocytes. Dexamethasone 38-51 interleukin 6 Homo sapiens 97-110 1667244-3 1991 Its secretion is stimulated by interleukin 6 (IL-6) in a dose-dependent fashion and can further be positively modulated by dexamethasone. Dexamethasone 123-136 interleukin 6 Homo sapiens 46-50 1667244-5 1991 Incubation of HepG2 cells simultaneously with IL-6 and dexamethasone increases the magnitude of CRP release significantly above that seen with IL-6 alone. Dexamethasone 55-68 interleukin 6 Homo sapiens 143-147 1667244-6 1991 After preincubation with dexamethasone, the kinetics of CRP release, induced by IL-6, are increased and approach that observed in the case of alpha 1-acid glycoprotein (alpha 1-AGP) without dexamethasone pretreatment. Dexamethasone 25-38 interleukin 6 Homo sapiens 80-84 1724187-4 1991 The results also show a complex interaction between insulin, interleukin 6, and glucocorticoids because insulin is able to inhibit the dexamethasone induction of alpha 1-antichymotrypsin, and in the presence of interleukin 6, dexamethasone is able to regulate the production of fibrinogen and prealbumin. Dexamethasone 135-148 interleukin 6 Homo sapiens 61-74 1724187-4 1991 The results also show a complex interaction between insulin, interleukin 6, and glucocorticoids because insulin is able to inhibit the dexamethasone induction of alpha 1-antichymotrypsin, and in the presence of interleukin 6, dexamethasone is able to regulate the production of fibrinogen and prealbumin. Dexamethasone 226-239 interleukin 6 Homo sapiens 61-74 1871124-1 1991 Transfection of HeLa cells with cDNA vectors expressing the wild-type human glucocorticoid receptor (GR) enabled dexamethasone to strongly repress cytokine- and second messenger-induced expression of cotransfected chimeric reporter genes containing transcription regulatory DNA elements from the human interleukin 6 (IL-6) promoter. Dexamethasone 113-126 interleukin 6 Homo sapiens 302-315 1871124-1 1991 Transfection of HeLa cells with cDNA vectors expressing the wild-type human glucocorticoid receptor (GR) enabled dexamethasone to strongly repress cytokine- and second messenger-induced expression of cotransfected chimeric reporter genes containing transcription regulatory DNA elements from the human interleukin 6 (IL-6) promoter. Dexamethasone 113-126 interleukin 6 Homo sapiens 317-321 2045425-4 1991 The mechanism of dexamethasone-mediated repression of IL-6 gene expression in epithelial cells involves occlusion of the entire MRE enhancer region and of the core-promoter elements (TATA-box and RNA start site) by ligand-activated glucocorticoid receptor. Dexamethasone 17-30 interleukin 6 Homo sapiens 54-58 2007786-6 1991 Addition of hydrocortisone, prednisolone, or dexamethasone immediately after UVB irradiation significantly blocked UVB or IL-1-induced IL-6 mRNA expression and production by EC. Dexamethasone 45-58 interleukin 6 Homo sapiens 135-139 2046859-2 1991 The glucocorticoid hormone dexamethasone (DEX) dose-dependently inhibited the release of IL-6, the IC50 being 2.43 +/- 0.93 nM. Dexamethasone 27-40 interleukin 6 Homo sapiens 89-93 2046859-2 1991 The glucocorticoid hormone dexamethasone (DEX) dose-dependently inhibited the release of IL-6, the IC50 being 2.43 +/- 0.93 nM. Dexamethasone 42-45 interleukin 6 Homo sapiens 89-93 2046859-4 1991 The adenylate cyclase activator forskolin increased IL-6 release in aggregate cultures in the presence of DEX. Dexamethasone 106-109 interleukin 6 Homo sapiens 52-56 1707461-4 1990 Dexamethasone added to the cultures at 10(-7) M concentration suppressed the constitutive expression of the IL-6 gene. Dexamethasone 0-13 interleukin 6 Homo sapiens 108-112 1707461-5 1990 At a concentration of 10(-5) M, dexamethasone partially suppressed the IL-1 enhanced expression of IL-6. Dexamethasone 32-45 interleukin 6 Homo sapiens 99-103 1651357-6 1991 Similar results were obtained for the effect of dexamethasone on the induction of SAA by IL-6 plus IL-1 alpha. Dexamethasone 48-61 interleukin 6 Homo sapiens 89-93 1651357-12 1991 These data indicate that IL-6, IL-1 alpha, TNF-alpha, and dexamethasone in various combinations are all capable of influencing synthesis of SAA in Hep 3B cells, whereas only IL-6, IL-1 alpha, and dexamethasone can influence CRP synthesis. Dexamethasone 196-209 interleukin 6 Homo sapiens 25-29 2031150-5 1991 Cortisol and dexamethasone, but not oestrogen, progesterone, or testosterone, dramatically suppressed the LPS-stimulated secretion of IL-6 by fetal Kupffer cells. Dexamethasone 13-26 interleukin 6 Homo sapiens 134-138 2233715-2 1990 The mechanism of the efficient repression of the IL-6 promoter by dexamethasone (Dex) was investigated in HeLa cells transiently transfected with plasmid constructs containing different IL-6 promoter elements linked to the herpesvirus thymidine kinase gene (tk) promoter and the bacterial chloramphenicol acetyltransferase gene (cat) and cotransfected with cDNA vectors constitutively expressing either the active wild-type or inactive mutant human glucocorticoid receptor (GR). Dexamethasone 66-79 interleukin 6 Homo sapiens 49-53 2233715-2 1990 The mechanism of the efficient repression of the IL-6 promoter by dexamethasone (Dex) was investigated in HeLa cells transiently transfected with plasmid constructs containing different IL-6 promoter elements linked to the herpesvirus thymidine kinase gene (tk) promoter and the bacterial chloramphenicol acetyltransferase gene (cat) and cotransfected with cDNA vectors constitutively expressing either the active wild-type or inactive mutant human glucocorticoid receptor (GR). Dexamethasone 81-84 interleukin 6 Homo sapiens 49-53 2233715-4 1990 The induction by pseudorabies virus of an IL-6 construct containing the IL-6 TATA box and the RNA start site ("initiator" or Inr element) but not the MRE region was also repressed by Dex in the presence of wild-type GR. Dexamethasone 183-186 interleukin 6 Homo sapiens 42-46 2233715-4 1990 The induction by pseudorabies virus of an IL-6 construct containing the IL-6 TATA box and the RNA start site ("initiator" or Inr element) but not the MRE region was also repressed by Dex in the presence of wild-type GR. Dexamethasone 183-186 interleukin 6 Homo sapiens 72-76 34955648-16 2021 Co- and Ni-stimulated IL-6 secretion is inhibited by DEX. Dexamethasone 53-56 interleukin 6 Homo sapiens 22-26 1966584-3 1990 The de novo conversion of cultured HSF was demonstrated in a large fraction of ST:FeSV (FeLV)-transformed foci in the presence of dexamethasone (DX). Dexamethasone 130-143 interleukin 6 Homo sapiens 35-38 2194956-4 1990 Dexamethasone reduced interleukin-6 secretion, the PMNL response, and bacterial clearance. Dexamethasone 0-13 interleukin 6 Homo sapiens 22-35 2163835-2 1990 Treatment of HepG2 cells with dexamethasone led to a time- and dose-dependent up-regulation of IL-6-receptor mRNA levels. Dexamethasone 30-43 interleukin 6 Homo sapiens 95-99 2163835-3 1990 By the use of cross-linking this effect was also seen at the protein level, where all three IL-6-binding complexes increased upon incubation of HepG2 cells with dexamethasone. Dexamethasone 161-174 interleukin 6 Homo sapiens 92-96 2163835-4 1990 Under conditions of IL-6-receptor up-regulation by dexamethasone, gamma-fibrinogen mRNA induction by IL-6 is stronger and occurs earlier than without dexamethasone. Dexamethasone 51-64 interleukin 6 Homo sapiens 20-24 2163835-4 1990 Under conditions of IL-6-receptor up-regulation by dexamethasone, gamma-fibrinogen mRNA induction by IL-6 is stronger and occurs earlier than without dexamethasone. Dexamethasone 51-64 interleukin 6 Homo sapiens 101-105 1689350-7 1990 In the whole blood culture, it was shown that expression of IL-6 mRNA by monocytes was inhibited by dexamethasone, but not by cyclosporin A. Dexamethasone 100-113 interleukin 6 Homo sapiens 60-64 33771121-0 2021 Mutant glucocorticoid receptor binding elements on the interleukin-6 promoter regulate dexamethasone effects. Dexamethasone 87-100 interleukin 6 Homo sapiens 55-68 34943719-6 2021 Herein, we demonstrated that dexamethasone binds with high affinity to interlukin-1 (IL-1), IL-6, IL-8, IL-12, IL-21, INF2, TGFbeta-1, INF-gamma, CXCL8, some of the receptors, IL-1R, IL-21R, IFNGR, INFAR, IL-6alphaR-gp130, ST2 and the SARS-CoV-2 protein NSP macro X, and 3CLpro, forming stable drug-protein complexes. Dexamethasone 29-42 interleukin 6 Homo sapiens 92-96 35422571-8 2022 After the Analyze we suggest the use of response nutraceutical therapy associated with dexamethasone can reduce the expression of Interlukina-6(IL-6) and myalgia due to COVID-19. Dexamethasone 87-100 interleukin 6 Homo sapiens 144-148 34682144-9 2021 Following dexamethasone treatment, there were significant decreases in respiratory severity score (RSS), percent CD4+IL-6+ cells, CD8+IL-6+ cells, CXCR3+IL-6+ cells, and CXCR3+IL-2+ cells and total intracellular IFN-gamma in TA. Dexamethasone 10-23 interleukin 6 Homo sapiens 117-121 34682144-9 2021 Following dexamethasone treatment, there were significant decreases in respiratory severity score (RSS), percent CD4+IL-6+ cells, CD8+IL-6+ cells, CXCR3+IL-6+ cells, and CXCR3+IL-2+ cells and total intracellular IFN-gamma in TA. Dexamethasone 10-23 interleukin 6 Homo sapiens 134-138 34682144-9 2021 Following dexamethasone treatment, there were significant decreases in respiratory severity score (RSS), percent CD4+IL-6+ cells, CD8+IL-6+ cells, CXCR3+IL-6+ cells, and CXCR3+IL-2+ cells and total intracellular IFN-gamma in TA. Dexamethasone 10-23 interleukin 6 Homo sapiens 153-157 34483461-2 2021 The objective of our study is to unravel the binding mechanism of the Food and Drug Administration (FDA)-approved dexamethasone (Dex) and boceprevir (Boc) drugs with selected COVID-19 protein targets SARS-CoV-2 spike protein C-terminal domain (spike-CTD), main protease (Mpro), and interleukin-6 (IL-6). Dexamethasone 114-127 interleukin 6 Homo sapiens 282-295 34483461-2 2021 The objective of our study is to unravel the binding mechanism of the Food and Drug Administration (FDA)-approved dexamethasone (Dex) and boceprevir (Boc) drugs with selected COVID-19 protein targets SARS-CoV-2 spike protein C-terminal domain (spike-CTD), main protease (Mpro), and interleukin-6 (IL-6). Dexamethasone 114-127 interleukin 6 Homo sapiens 297-301 34483461-2 2021 The objective of our study is to unravel the binding mechanism of the Food and Drug Administration (FDA)-approved dexamethasone (Dex) and boceprevir (Boc) drugs with selected COVID-19 protein targets SARS-CoV-2 spike protein C-terminal domain (spike-CTD), main protease (Mpro), and interleukin-6 (IL-6). Dexamethasone 129-132 interleukin 6 Homo sapiens 282-295 34441262-9 2021 The odds ratio of IL-6 which was crude and adjusted for dexamethasone administration initiated before laboratory measurement, showed the high value of 29.1 (5.6-295.6) and 53.9 (4.5-3242.8), respectively. Dexamethasone 56-69 interleukin 6 Homo sapiens 18-22 34253189-0 2021 Correction to: Mutant glucocorticoid receptor binding elements on the interleukin-6 promoter regulate dexamethasone effects. Dexamethasone 102-115 interleukin 6 Homo sapiens 70-83 35610009-8 2022 Compared with the Model group, the dexamethasone significantly reduced the expression of p-JAK2/JAK2, p-STAT3/STAT3, and IL-6 ( < 0.01). Dexamethasone 35-48 interleukin 6 Homo sapiens 121-125 35454970-8 2022 In addition, inhibition of interleukin (IL)-6 with dexamethasone, tocilizumab, and sarilumab effectively treats cytokine storm and significantly reduces mortality caused by COVID-19. Dexamethasone 51-64 interleukin 6 Homo sapiens 27-45 34955648-0 2021 Metal-Stimulated Interleukin-6 Production Through a Proton-Sensing Receptor, Ovarian Cancer G Protein-Coupled Receptor 1, in Human Bronchial Smooth Muscle Cells: A Response Inhibited by Dexamethasone. Dexamethasone 186-199 interleukin 6 Homo sapiens 17-30 34955648-13 2021 DEX inhibited Co- and Ni-stimulated IL-6 secretion by human BSMCs as well as pH 6.3-stimulated IL-6 secretion in a dose-dependent manner. Dexamethasone 0-3 interleukin 6 Homo sapiens 36-40 34955648-13 2021 DEX inhibited Co- and Ni-stimulated IL-6 secretion by human BSMCs as well as pH 6.3-stimulated IL-6 secretion in a dose-dependent manner. Dexamethasone 0-3 interleukin 6 Homo sapiens 95-99 34682144-11 2021 To our knowledge, this is the first study demonstrating that dexamethasone reduced T-cell IL-6 and this reduction was associated with improved RSS in pre-term infants with evolving BPD. Dexamethasone 61-74 interleukin 6 Homo sapiens 90-94 35422571-9 2022 Conclusion: According the scientific literature nutraceutical therapy associated with dexamethasone can reduce the expression of Interlukina-6(IL-6) and myalgia due to COVID-19. Dexamethasone 86-99 interleukin 6 Homo sapiens 143-147 35060899-9 2022 Cells with TT variant exposed to an MDA5 agonist showed an increase in IL6 expression after dexamethasone treatment. Dexamethasone 92-105 interleukin 6 Homo sapiens 71-74 35060899-11 2022 Patients with a TT variant treated with dexamethasone showed an increased hospital mortality (HR: 2.19, 95% CI: 1.01-4.87) and serum IL-6. Dexamethasone 40-53 interleukin 6 Homo sapiens 133-137 2454192-2 1988 In the presence of 10(-6) M dexamethasone beta-fibrinogen mRNA levels increased 6-fold after addition of recombinant human IL 6 (rhIL 6). Dexamethasone 28-41 interleukin 6 Homo sapiens 123-127 2476083-8 1989 Both dexamethasone and 13-cis-RA also reduced the mRNA level of glyceraldehyde-3-phosphate dehydrogenase, indicating that glucocorticoids and retinoids have both similar and different effects on gene expression in HSF. Dexamethasone 5-18 interleukin 6 Homo sapiens 214-217 33998893-5 2021 Relative to the LPS-activated and untreated control (M[LPS]), both 25 muM CBD and 10 muM Dex reduced expression of pro-inflammatory markers-tumor necrosis factor alpha, interleukin 1 beta, and regulated on activation, normal T cell expressed and secreted (RANTES)-as well as the pleiotropic marker interleukin-6 (IL-6). Dexamethasone 89-92 interleukin 6 Homo sapiens 298-311 33887367-6 2021 The signature apparently relates to TNF- alpha, IL-1alpha, IL-1beta, IFN-alpha, IFN-beta, and IFN-gamma signaling, but not IL-6 signaling, suggesting that therapeutic effect of dexamethasone in COVID-19 does not involve IL-6 pathway. Dexamethasone 177-190 interleukin 6 Homo sapiens 220-224 33259720-7 2021 There were significant differences in inflammatory markers between the two groups: interleukin-6 (p = 0.0001), procalcitonin (p = 0.0001), and C-reactive protein (p = 0.0001) were lower in the dexamethasone group. Dexamethasone 193-206 interleukin 6 Homo sapiens 83-96 2824651-4 1987 The increase in IFN-beta 2 mRNA level caused by LPS in FS-4 cells is detected within 30 min after addition of LPS, is sustained for at least 20 h thereafter, appears to involve the protein kinase C signal transduction pathway, does not require new protein synthesis, and is inhibited by dexamethasone in a dose-dependent fashion (in the range 10(-6)-10(-8) M). Dexamethasone 287-300 interleukin 6 Homo sapiens 16-26 3040777-8 1987 Dexamethasone inhibited the increase of IFN-beta 2 mRNA levels by IL-1 or TNF. Dexamethasone 0-13 interleukin 6 Homo sapiens 40-50 33571577-7 2021 Moreover, 24-hour treatment with the synthetic glucocorticoid dexamethasone prevented the effects of LPS stimulation on IL-6, StAR and DAX-1 mRNA in ATC7 cells co-cultured with THP1 cells. Dexamethasone 62-75 interleukin 6 Homo sapiens 120-124 33998893-5 2021 Relative to the LPS-activated and untreated control (M[LPS]), both 25 muM CBD and 10 muM Dex reduced expression of pro-inflammatory markers-tumor necrosis factor alpha, interleukin 1 beta, and regulated on activation, normal T cell expressed and secreted (RANTES)-as well as the pleiotropic marker interleukin-6 (IL-6). Dexamethasone 89-92 interleukin 6 Homo sapiens 313-317 33998893-7 2021 Dex further reduced secreted levels of monocyte chemoattractant protein-1 in addition to suppressing IL-6 and VEGF beyond treatments with CBD. Dexamethasone 0-3 interleukin 6 Homo sapiens 101-105 32927792-7 2020 Both formulations, however, delivered sufficient amounts of DXM to effectively suppress the production of interleukin-6 (IL-6), interleukin-8 (IL-8) and Thymic Stromal Lymphopoietin (TSLP). Dexamethasone 60-63 interleukin 6 Homo sapiens 106-119 33657083-6 2021 GCR was assessed as the concentration of dexamethasone required to decrease the stimulated IL-6 response by 50% (IC50), with higher concentrations indicating greater GCR. Dexamethasone 41-54 interleukin 6 Homo sapiens 91-95 33145838-4 2021 We observed inhibition of IL-6 and CXCL8 secretion from both lung fibroblast models by dexamethasone (maximal inhibition 40 - 90%) and the p38 MAPK inhibitor BIRB (maximal inhibition 30 - 60%), used alone and evidence of increased anti-inflammatory effects when used in combination. Dexamethasone 87-100 interleukin 6 Homo sapiens 26-30 32924825-8 2022 Dex showed stronger affinity to its theoretical (glucocorticoid) receptor with a superior docking score of -14.7 and a good binding energy value of -147.48 kcal/mol; while short hydrogen bond distances were observed in both Mpro and IL-6 when compared to glucocorticoid receptor. Dexamethasone 0-3 interleukin 6 Homo sapiens 233-237 33672354-8 2021 Celecoxib and dexamethasone-loaded nanoparticles reduced the release of different inflammatory mediators (NO, TNF-alpha, IL-1beta, IL-6, PGE2 and IL-10) by lipopolysaccharide (LPS)-stimulated RAW264.7. Dexamethasone 14-27 interleukin 6 Homo sapiens 131-135 33413425-3 2021 Different concentrations of Dex were used to attenuate the inflammation induced by IL-1beta, and its effect was assessed via RT-PCR to detect inflammatory cytokine-related mRNA levels, including those of IKbeta-alpha, IKKbeta, IL-6, IL-8, and TNF-alpha. Dexamethasone 28-31 interleukin 6 Homo sapiens 227-231 33023630-9 2020 As previously reported, DEX or IgG alone significantly suppressed TNF-alpha-induced production of IL-6 and G-CSF and mRNA expression, but induction of those cytokines by IL-1 s (IL-1alpha and IL-1beta) was resistant to high-dose IgG. Dexamethasone 24-27 interleukin 6 Homo sapiens 98-102 32927792-7 2020 Both formulations, however, delivered sufficient amounts of DXM to effectively suppress the production of interleukin-6 (IL-6), interleukin-8 (IL-8) and Thymic Stromal Lymphopoietin (TSLP). Dexamethasone 60-63 interleukin 6 Homo sapiens 121-125 32194233-5 2020 We demonstrated that dexamethasone in vitro given for 24 hours and followed by a 24-hour rest interval before an immune challenge potentiates inflammatory effects in these neural cells, that is, increases the IL-6 protein secretion induced by stimulation with IL-1beta (10ng/mL for 24 hours) by +49% (P<0.05) at a concentration of 100nM and by +70% (P<0.01) for 1muM. Dexamethasone 21-34 interleukin 6 Homo sapiens 209-213 32962815-8 2020 While treatment of U937 cells with interleukin 6 (IL-6) resulted in increased expression of hepcidin, dexamethasone treatment resulted in reduced hepcidin synthesis relative to E2- or dexamethasone + E2-treated cells; IL-6 silencing also resulted in reduced hepcidin synthesis in U937 cells. Dexamethasone 102-115 interleukin 6 Homo sapiens 218-222 31758423-9 2020 IGU, MTX, and DXM dose dependently decreased the secretion of TNF-alpha, IL-1beta, IL-6, and IL-8 in neutrophils and PBMCs (P < 0.05); the inhibitory effect of IGU was not significantly different from that of MTX and DXM. Dexamethasone 14-17 interleukin 6 Homo sapiens 83-87 32615160-12 2020 In addition, combining bergenin and dexamethasone (DEX) yielded additive effects on the reduction of IL-6 and IL-8 expression. Dexamethasone 36-49 interleukin 6 Homo sapiens 101-105 32615160-12 2020 In addition, combining bergenin and dexamethasone (DEX) yielded additive effects on the reduction of IL-6 and IL-8 expression. Dexamethasone 51-54 interleukin 6 Homo sapiens 101-105 32547185-13 2020 Dexamethasone 4 mg and 8 mg decreased the ratio IL-6/IL-10 (b=-2.60 (-3.93 to -1.26), P<0.001 and b=-3.59 (-5.04 to -2.13), P<0.001, respectively). Dexamethasone 0-13 interleukin 6 Homo sapiens 48-52 33073254-7 2020 As expected, DEX treatment suppressed multiple LPS-induced pro-inflammatory cytokines (IFN-gamma, IL-6, IL-8, IL-1beta, .TNF-alpha) by >85% and increased the anti-inflammatory cytokine IL-10 by 80%. Dexamethasone 13-16 interleukin 6 Homo sapiens 98-102 33073254-8 2020 Inhibiting Complex I potentiated DEX suppression of IL-6 by a further 12% (d = 0.73), indicating partial mitochondrial modulation of glucocorticoid sensitivity. Dexamethasone 33-36 interleukin 6 Homo sapiens 52-56 32068891-12 2020 IL-6 produced by macrophages in response to LPS- treated dentine impeded SCAP migration (p < 0.001), diminished on CSnp and Dex-CSnp conditioning groups (p < 0.01). Dexamethasone 127-130 interleukin 6 Homo sapiens 0-4 32266020-6 2020 The percentage of maximal inhibition of IL-6 by DEX was presented as Emax. Dexamethasone 48-51 interleukin 6 Homo sapiens 40-44 32266020-11 2020 Moreover, IL-35 enhanced DEX-suppressed IL-6 production and the DEX-induced upregulation of the MKP-1 mRNA expression level in monocytes from both patient groups (P<0.01). Dexamethasone 25-28 interleukin 6 Homo sapiens 40-44 32347005-6 2020 RESULTS: The CRP and IL-6 levels were lower in the TXA + DEX group than in the TXA group (all P < 0.001) at 24 h, 48 h, and 72 h postoperatively. Dexamethasone 57-60 interleukin 6 Homo sapiens 21-25 31511352-4 2019 Activation of glucocorticoid receptor (GR) by the synthetic glucocorticoid dexamethasone upregulated FADS1 and IL6, but downregulated TNFalpha expression. Dexamethasone 75-88 interleukin 6 Homo sapiens 111-114 31412983-10 2020 RESULTS: Compared with AMSCs from severe asthma patients, dexamethasone inhibited cytokines (CCL5, CCL11 and IL-6) and promoted the phosphorylation of GR more significantly in normal AMSCs. Dexamethasone 58-71 interleukin 6 Homo sapiens 109-113 31338585-7 2019 Both dexamethasone and tocilizumab influenced IL-6 and IL-6Rs levels in patients" group. Dexamethasone 5-18 interleukin 6 Homo sapiens 46-50 31338585-8 2019 Supernatants obtained from PBMCs treated with dexamethasone showed 77.2% and 82.8% lower IL-6 levels compared with those cultured with placebo and tocilizumab, respectively. Dexamethasone 46-59 interleukin 6 Homo sapiens 89-93 31338585-11 2019 CONCLUSIONS: Both dexamethasone and tocilizumab affect the IL-6/sIL-6R system. Dexamethasone 18-31 interleukin 6 Homo sapiens 59-63 31517562-7 2019 Fluticasone propionate (FP) and dexamethasone (DEX) suppressed IL-6 and IL-8 production in BEAS-2B cells, but clarithromycin (CAM) failed to do so. Dexamethasone 32-45 interleukin 6 Homo sapiens 63-67 31517562-7 2019 Fluticasone propionate (FP) and dexamethasone (DEX) suppressed IL-6 and IL-8 production in BEAS-2B cells, but clarithromycin (CAM) failed to do so. Dexamethasone 47-50 interleukin 6 Homo sapiens 63-67 31511352-5 2019 Furthermore, dexamethasone was synergistic or additive with E2 in upregulating FADS1 and IL6 expression, whereas it selectively and constantly suppressed TNFalpha expression induced by E2 in LTED breast cancer cells. Dexamethasone 13-26 interleukin 6 Homo sapiens 89-92 30501618-9 2018 CONCLUSIONS: The administration of 10 mg dexamethasone 1 h before the surgery, and repeated at 6 h postoperatively can significantly reduce the level of postoperative CRP and IL-6 and the incidence of PONV, relieve pain, achieve an additional analgesic effect, and improve the early ROM compared with the other two groups in TKA. Dexamethasone 41-54 interleukin 6 Homo sapiens 175-179 31571855-5 2019 The efficiency of the released DEX in reducing inflammation markers (tumor necrosis factor alpha and IL-6) produced by human monocytes and macrophages was similar to the pure drug at the same concentration without negative impacts on the viability and morphology of these cells. Dexamethasone 31-34 interleukin 6 Homo sapiens 101-105 31441836-9 2019 CONCLUSION: The combined administration of TXA + Dexa significantly reduced the level of postoperative CRP and IL-6, relieve postoperative pain, ameliorate the incidence of POVN, provide additional analgesic and antiemetic effects, reduce postoperative fatigue, and improve ROM, without increasing the risk of complications in primary TKA. Dexamethasone 49-53 interleukin 6 Homo sapiens 111-115 31572383-13 2019 Dexamethasone and budesonide induced sftpd transcription and translation in human type II alveolar epithelial cells in a glucocorticoid receptor and STAT3 (an IL-6 responsive transcription factor) dependent manner. Dexamethasone 0-13 interleukin 6 Homo sapiens 159-163 31069604-6 2019 DEX (1.000 nM) treatment in PBMC of SSc patients stimulated with anti-CD3 and anti-CD28 promoted a significant reduction in IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-gamma, TNF, IL-1beta (p < 0.001 for all), and IL-17F (p = 0.023) cytokines levels. Dexamethasone 0-3 interleukin 6 Homo sapiens 136-140 31069604-8 2019 In PBMC from healthy volunteers, we observed that DEX treatment significantly reduced IL-4, IFN-gamma (p = 0.003 for both), IL-6, IL-10, IL-17A, and TNF (p = 0.002 for all) cytokines. Dexamethasone 50-53 interleukin 6 Homo sapiens 124-128 31274789-10 2019 The Dex group had significantly lower interleukin (IL)-1beta levels in the lung tissue compared to the other groups (p < 0.05) and significantly lower IL-6 levels compared to the Ami and Mil groups (p < 0.05). Dexamethasone 4-7 interleukin 6 Homo sapiens 154-158 30192654-4 2019 Treatment of human adipose tissue with 10-1000 nM Dex decreased ATX secretion, increased LPP1 expression, and decreased mRNA expressions of IL-6, TNF-alpha, peroxisome proliferator-activated receptor (PPAR)-gamma, and adiponectin. Dexamethasone 50-53 interleukin 6 Homo sapiens 140-144 30238726-11 2018 Univariate analysis showed that the level of IL-6 in serum at 1 day after operation was significantly higher in variables as follows: age, diagnosis, history of lung infection, range of motion, preoperative levels of CRP and IL-6 in serum, intravenous dosage of tranexamic acid and dexamethasone on day of operation ( P<0.05). Dexamethasone 282-295 interleukin 6 Homo sapiens 45-49 30026080-4 2018 We show that the presence of the dexamethasone prodrug LD003 effectively suppresses production of cytokines such as KC-GRO, TNFalpha, IL-1beta and IL-6 following intravenous administration of LNP loaded with immune stimulatory oligodeoxynucleotides containing cytosine-guanine dinucleotide motifs. Dexamethasone 33-46 interleukin 6 Homo sapiens 147-151 29936334-6 2018 GR sensitivity was evaluated in vitro by assessing the Dex inhibition of lipopolysaccharide (LPS)-stimulated IL-6 and TNF-alpha levels. Dexamethasone 55-58 interleukin 6 Homo sapiens 109-113 30236152-8 2018 In contrast, DEX was the strongest inhibitor of IL-6, IL-8, and tissue-destructive enzymes in RASF. Dexamethasone 13-16 interleukin 6 Homo sapiens 48-52 30238726-13 2018 Conclusion: Range of motion less than 90 , intravenous dosage of tranexamic acid on day of operation less than 3 g, and dosage of dexamethasone on day of operation less than 10 mg were independent risk factors that resulted in increased level of IL-6 in serum at 1 day after TKA. Dexamethasone 130-143 interleukin 6 Homo sapiens 246-250 29715306-11 2018 (PTX+DEX) synergistically decreased LPS- and LPS/ATP-induced TNF, IL-1beta, and IL-6, and R848-induced IL-1beta and interferon-alpha, while (PTX+AZI) synergistically decreased induction of TNF, IL-1beta, and IL-6. Dexamethasone 5-8 interleukin 6 Homo sapiens 208-212 28474088-12 2018 Conclusions Administering two doses of low-dose perioperative dexamethasone for patients receiving total knee arthroplasty reduces postoperative CRP and IL-6 levels, provides additional analgesic effect, and reduces the PONV incidence and postoperative fatigue, without increasing the risk of early surgical wound infection and gastrointestinal haemorrhage. Dexamethasone 62-75 interleukin 6 Homo sapiens 153-157 29715306-9 2018 DEX inhibited IL-10 in newborn, and TNF, IL-1beta, IL-6 and interferon-alpha in newborn and adult blood. Dexamethasone 0-3 interleukin 6 Homo sapiens 51-55 29302812-2 2018 RESULTS: Four mRNAs were upregulated and 12 were downregulated when the results of dexamethasone at 24 h were compared with the control at 24 h. Expressions of SIRT1 and IL6 were decreased in dexamethasone at 24 h but expression of EDN1 was increased. Dexamethasone 192-205 interleukin 6 Homo sapiens 170-173 29715306-11 2018 (PTX+DEX) synergistically decreased LPS- and LPS/ATP-induced TNF, IL-1beta, and IL-6, and R848-induced IL-1beta and interferon-alpha, while (PTX+AZI) synergistically decreased induction of TNF, IL-1beta, and IL-6. Dexamethasone 5-8 interleukin 6 Homo sapiens 80-84 29302812-0 2018 Dexamethasone downregulates SIRT1 and IL6 and upregulates EDN1 genes in stem cells derived from gingivae via the AGE/RAGE pathway. Dexamethasone 0-13 interleukin 6 Homo sapiens 38-41 29302812-3 2018 CONCLUSIONS: Application of dexamethasone reduced the expression of SIRT1 and IL6 but enhanced the expression of EDN1 of stem cells. Dexamethasone 28-41 interleukin 6 Homo sapiens 78-81 29302812-2 2018 RESULTS: Four mRNAs were upregulated and 12 were downregulated when the results of dexamethasone at 24 h were compared with the control at 24 h. Expressions of SIRT1 and IL6 were decreased in dexamethasone at 24 h but expression of EDN1 was increased. Dexamethasone 83-96 interleukin 6 Homo sapiens 170-173 29248584-8 2018 Cells treated with dexamethasone alone at both the concentrations inhibit the mRNAs expression of IL-1beta, IL-6 and TNF-alpha compared to control. Dexamethasone 19-32 interleukin 6 Homo sapiens 108-112 28647788-11 2018 CONCLUSIONS: The administration of two low-dose peri-operative dexamethasone can effectively reduce the post-operative level of CRP and IL-6, provide additional pain and nausea control, ameliorate post-operative fatigue, enhance mobility, and shorten post-operative LOS following THA, without increasing the risk of infection and gastrointestinal hemorrhage. Dexamethasone 63-76 interleukin 6 Homo sapiens 136-140 28420398-7 2017 RESULTS: Dexamethasone significantly inhibited NTHi induced TNF-alpha, IL-6 and IL-10 from COPD macrophages but, CXCL8 was not suppressed. Dexamethasone 9-22 interleukin 6 Homo sapiens 71-75 29521042-10 2018 Additional application of dexamethasone to SCP-1 cells further increased the RANKL/OPG ratio 3-fold, but decreased IL-6 and IL-1beta expression to 10% and 50%, respectively. Dexamethasone 26-39 interleukin 6 Homo sapiens 115-119 29398016-15 2018 The allergens (Der p2 and Der p3)-induced IL-6/IL-8 expression and NCA released from Beas-2B could be downregulated by dexamethasone and transcription factor inhibitor SP600125. Dexamethasone 119-132 interleukin 6 Homo sapiens 42-46 29140074-6 2017 Additionally, liposomal dexamethasone reduced proinflammatory mediator expression (particularly IL-6 and TNF-alpha) in lipopolysaccharide-stimulated human gingival fibroblasts and human mesenchymal stem cells. Dexamethasone 24-37 interleukin 6 Homo sapiens 96-100 28167299-9 2017 Calcipotriol and dexamethasone additively reduced the secretions of IL-6, IFN-gamma, basic FGF and VEGF in TNF-alpha stimulated SSC. Dexamethasone 17-30 interleukin 6 Homo sapiens 68-72 28529032-0 2017 Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis. Dexamethasone 45-58 interleukin 6 Homo sapiens 123-127 28529032-2 2017 Cereblon is probably targeted by both lenalidomide and dexamethasone, which leads to synergistic cytotoxicity in MCL by inhibiting the interleukin-6/signal transducer and activator of transcription 3 (IL-6/STAT3), phosphatidylinositol 3-kinase (PI3K)/AKT and AKT2/Forkhead box O3 (FOXO3A)/BCL2-like 11 (BIM) pathways. Dexamethasone 55-68 interleukin 6 Homo sapiens 201-205 26825339-9 2016 IL-6 mRNA expression and protein secretion was significantly repressed by dexamethasone acting in a temporally distinct manner to increase MKP-1, deactivate p38 MAPK, and modulate TTP phosphorylation status. Dexamethasone 74-87 interleukin 6 Homo sapiens 0-4 27443878-10 2016 Intraperitoneal administration of dexamethasone completely abrogated IL-33-mediated peritoneal neutrophil recruitment and prevented plasma IL-6 elevation. Dexamethasone 34-47 interleukin 6 Homo sapiens 139-143 27176565-6 2017 Under these conditions, dexamethasone is non-toxic and maintains the viability of chondrocytes exposed chronically to such cytokines as interleukin (IL) -1, IL-6, and tumor necrosis factor-alpha. Dexamethasone 24-37 interleukin 6 Homo sapiens 157-161 27998979-11 2017 Dexamethasone induces the recruitment of ACTN4 and GR to putative GREs in dexamethasone-transactivated promoters, SERPINE1, ANGPLT4, CCL20, and SAA1 as well as the NF-kappaB (p65) binding sites on GR-transrepressed promoters such as IL-1beta, IL-6, and IL-8 Taken together, our data establish ACTN4 as a transcriptional co-regulator that modulates both dexamethasone-transactivated and -transrepressed genes in podocytes. Dexamethasone 0-13 interleukin 6 Homo sapiens 243-247 27998979-11 2017 Dexamethasone induces the recruitment of ACTN4 and GR to putative GREs in dexamethasone-transactivated promoters, SERPINE1, ANGPLT4, CCL20, and SAA1 as well as the NF-kappaB (p65) binding sites on GR-transrepressed promoters such as IL-1beta, IL-6, and IL-8 Taken together, our data establish ACTN4 as a transcriptional co-regulator that modulates both dexamethasone-transactivated and -transrepressed genes in podocytes. Dexamethasone 74-87 interleukin 6 Homo sapiens 243-247 25917060-14 2016 CONCLUSION: Dexamethasone caused quantitative suppression of Interleukin-6 and increased Interleukin-10 activation, contributing to reduced immunopathology, but it did not translate into clinical benefit in the short term. Dexamethasone 12-25 interleukin 6 Homo sapiens 61-74 27477309-5 2016 Under these conditions, Pam3CSK4 induces corticosteroid insensitivity; demonstrated by substantially reduced ability of the corticosteroid dexamethasone to repress TNFalpha-induced interleukin 6 secretion. Dexamethasone 139-152 interleukin 6 Homo sapiens 181-194 26940199-9 2016 Finally, ICC showed, after 24 hrs of CTLA4-Ig-DEX or CTLA4-Ig-DEX-MTX treatment a reduction (p<0.05) of IL-1beta and IL-6 expression, versus CNT; DEX alone reduced only IL-1beta (p<0.05). Dexamethasone 46-49 interleukin 6 Homo sapiens 120-124 26940199-9 2016 Finally, ICC showed, after 24 hrs of CTLA4-Ig-DEX or CTLA4-Ig-DEX-MTX treatment a reduction (p<0.05) of IL-1beta and IL-6 expression, versus CNT; DEX alone reduced only IL-1beta (p<0.05). Dexamethasone 62-65 interleukin 6 Homo sapiens 120-124 26667403-10 2016 CRP, IL-6, and cortisol were significantly lower in the dexamethasone group compared with the control group during the 24 hours after UAE. Dexamethasone 56-69 interleukin 6 Homo sapiens 5-9 25556347-8 2015 Importantly, known suppressive effects of dexamethasone, a drug employed for the treatment of inflammatory bowel diseases, on leucocyte migration, IL8, IL6, and TNF-alpha production as well as CD86 surface expression by myeloid cells were observed in this model. Dexamethasone 42-55 interleukin 6 Homo sapiens 152-155 25683698-9 2015 GR sensitivity was evaluated in vitro in isolated peripheral blood mononuclear cells using the dexamethasone inhibition of lipopolysaccharide-stimulated IL-6 levels. Dexamethasone 95-108 interleukin 6 Homo sapiens 153-157 25749775-13 2015 Dexamethasone, calcitriol, anti-MD2/anti-TLR2 antibodies, and signalling inhibitors significantly reduced LPS+Der p2-induced IL-6/IL-8 secretion. Dexamethasone 0-13 interleukin 6 Homo sapiens 125-129 25943109-11 2015 Additionally, LPS pre-incubation: 1) reduced dexamethasone"s capacity to inhibit FBS-induced IL-6, CXCL8 and RANTES, 2) reduced dexamethasone-induced GRalpha nuclear translocation (only in NM fibroblasts), 3) did not alter GRalpha/GRbeta expression, 4) decreased GILZ expression, and 5) did not affect dexamethasone"s capacity to induce MKP-1 and GILZ expression. Dexamethasone 45-58 interleukin 6 Homo sapiens 93-97 25237168-8 2014 With dexamethasone, upregulation of PGE2, IL-6 and IL-8 was suppressed. Dexamethasone 5-18 interleukin 6 Homo sapiens 42-46 24880571-9 2014 Conversely, corticosterone, prednisone, and dexamethasone similarly inhibited cell invasion and expression of related genes, including MMP-9, VEGF, and IL-6, in GR-positive lines. Dexamethasone 44-57 interleukin 6 Homo sapiens 152-156 25358442-7 2015 RESULTS: Dexamethasone reduced LPS-induced TNFalpha, IL-6 and CXCL-8 in all groups, but maximum inhibition was significantly reduced for GINA3/4 compared with GINA2 and GINA1 (P < 0.01). Dexamethasone 9-22 interleukin 6 Homo sapiens 53-57 25330767-8 2015 The percent of SEB-stimulated IL-6 secretion (217.53% +- 89.51%) was also significantly reduced following exposure to verapamil (148.82% +- 79.15%, p < 0.05) but not dexamethasone (148.86% +- 145.24%). Dexamethasone 169-182 interleukin 6 Homo sapiens 30-34